var title_f17_49_18192="Talking tracheostomy tube";
var content_f17_49_18192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Talking tracheostomy tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Representation of the talking tracheostomy tube. Air is passed proximally beyond the vocal cords and phonation occurs when the port shown is manually occluded.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Current Respiratory Care 1988; BC Decker, Philadelphia, PA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18192=[""].join("\n");
var outline_f17_49_18192=null;
var title_f17_49_18193="Talc granulomatosis CT";
var content_f17_49_18193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Talc granulomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Talc granulomatosis in an intravenous drug addict with multiple, partially confluent, bilateral micronodules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18193=[""].join("\n");
var outline_f17_49_18193=null;
var title_f17_49_18194="Patient information: Carpal tunnel syndrome (The Basics)";
var content_f17_49_18194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16619\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/1/39955\">",
"         Carpal tunnel syndrome",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/11/7347\">",
"         Patient information: Hand pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/55/23411\">",
"         Patient information: Pregnancy symptoms (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Carpal tunnel syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/carpal-tunnel-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H4943701\">",
"      <span class=\"h1\">",
"       What is carpal tunnel syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Carpal tunnel syndrome is a condition that causes pain and numbness in the fingers and hands, and sometimes the arms. It happens when a nerve in the wrist called the &ldquo;median nerve&rdquo; gets pinched or squeezed.",
"     </p>",
"     <p>",
"      The median nerve goes through a tunnel in the wrist that is formed by the bones of the wrist and a tough band of tissue called a &ldquo;ligament&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef80666 \" href=\"UTD.htm?39/1/39955\">",
"       figure 1",
"      </a>",
"      ). Experts do not know exactly how the nerve can get pinched, but they think it might happen when:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tendons that go through the same tunnel get swollen (tendons are bands of tissue that connect muscles to bones) &nbsp;",
"       </li>",
"       <li>",
"        Tissues surrounding the tendons harden",
"       </li>",
"       <li>",
"        People hold their hands in a position that makes the tunnel smaller",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The median nerve carries signals about sensation&mdash;it tells the brain what the hand is &ldquo;feeling.&rdquo; It gets input from these parts of the hand:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Thumb",
"       </li>",
"       <li>",
"        Index finger",
"       </li>",
"       <li>",
"        Middle finger",
"       </li>",
"       <li>",
"        Parts of the ring finger",
"       </li>",
"       <li>",
"        Parts of the palm closest to the thumb &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4943716\">",
"      <span class=\"h1\">",
"       What are the symptoms of carpal tunnel syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include pain and tingling in the thumb and the index, middle, and ring fingers (",
"      <a class=\"graphic graphic_figure graphicRef80666 \" href=\"UTD.htm?39/1/39955\">",
"       figure 1",
"      </a>",
"      ). Often the symptoms affect both hands, but one hand might have worse symptoms than the other.",
"     </p>",
"     <p>",
"      In some cases, pain and tingling can extend to the whole hand or even up to the wrist and forearm. Rarely, pain and tingling extends past the elbow to the shoulder.",
"     </p>",
"     <p>",
"      Symptoms are usually worst at night and can even wake you up from sleep. The symptoms can also flare up when you do things that involve bending and unbending your wrist or raising your arms. Examples of activities that can trigger carpal tunnel symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Driving",
"       </li>",
"       <li>",
"        Reading",
"       </li>",
"       <li>",
"        Typing",
"       </li>",
"       <li>",
"        Holding a phone",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In many people, the symptoms come and go. But some people eventually have symptoms all the time. They can end up having trouble moving their fingers or controlling their grip.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4943731\">",
"      <span class=\"h1\">",
"       Is there a test for carpal tunnel syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Electrical tests of the nerves can show if you have carpal tunnel syndrome, but these tests are not always necessary.",
"     </p>",
"     <p>",
"      Your doctor will probably be able to tell if you have carpal tunnel syndrome by learning about your symptoms and doing an exam. During the exam, he or she might tap on or press on your wrist, or ask you to hold your hands in ways that are known to make symptoms worse.",
"     </p>",
"     <p>",
"      Electrical nerve tests can prove if you really have carpal tunnel syndrome. Doctors usually order these tests for people who might need surgery to treat their condition.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Nerve conduction studies",
"        </strong>",
"        &ndash; Nerve conduction studies can show whether the median nerve is carrying electrical signals the right way. In people with carpal tunnel syndrome, signals can be slow or weak. &nbsp;",
"       </li>",
"       <li>",
"        <strong>",
"         Electromyography",
"        </strong>",
"        &ndash; Electromyography, also called EMG, can show whether the muscles in the hand and wrist are responding the right way to electrical signals. This test is most useful in checking whether another condition besides carpal tunnel syndrome might be causing the symptoms.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4943746\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if you develop the symptoms described above, and they bother you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4943761\">",
"      <span class=\"h1\">",
"       How is carpal tunnel syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments are often combined and can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Wrist splints &ndash;",
"        </strong>",
"        Some people feel better if they wear splints at night that keep their hands in a &ldquo;neutral position.&rdquo; The neutral position is when the wrist is not bent forward or backward and the fingers are curled naturally toward the palm.",
"        <strong>",
"         &nbsp;",
"        </strong>",
"       </li>",
"       <li>",
"        <strong>",
"         Steroid shots or pills",
"        </strong>",
"        &ndash; Steroids are a group of medicines that control inflammation and swelling. To treat carpal tunnel syndrome, doctors sometimes inject steroids into the carpal tunnel. People who do not want to get a shot can take steroids in pill form instead. But the pills are less effective than the shot.",
"       </li>",
"       <li>",
"        <strong>",
"         Other physical treatments",
"        </strong>",
"        &ndash; There is some evidence that yoga or another treatment called &ldquo;carpal bone mobilization&rdquo; can help people with carpal tunnel syndrome. For carpal bone mobilization, a physical or occupational therapist moves your hand or wrist around in a special way, so that the bones in the wrist move.",
"       </li>",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &ndash; Doctors offer surgery to people who have severe symptoms and who do not get better with other treatments. Surgery for carpal tunnel syndrome involves cutting the ligament that stretches across the wrist to form the tunnel. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People sometimes try other treatments for carpal tunnel, such as special exercises called &ldquo;nerve-gliding&rdquo; exercises. Only the treatments listed above have been proven to work for carpal tunnel syndrome.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4943776\">",
"      <span class=\"h1\">",
"       Can carpal tunnel syndrome be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s unclear whether there is any way to prevent carpal tunnel syndrome. People sometimes think that the condition happens because they use a computer too much or do other movements repeatedly with their hands. The truth is, there is no good proof that doing repeated hand movements increases the risk of carpal tunnel syndrome.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4943791\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=see_link\">",
"       Patient information: Hand pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/55/23411?source=see_link\">",
"       Patient information: Pregnancy symptoms (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?17/49/18194?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16619 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18194=[""].join("\n");
var outline_f17_49_18194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4943701\">",
"      What is carpal tunnel syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4943716\">",
"      What are the symptoms of carpal tunnel syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4943731\">",
"      Is there a test for carpal tunnel syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4943746\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4943761\">",
"      How is carpal tunnel syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4943776\">",
"      Can carpal tunnel syndrome be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4943791\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16619\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/1/39955\">",
"      Carpal tunnel syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/55/23411?source=related_link\">",
"      Patient information: Pregnancy symptoms (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_49_18195="Pemphigoid gestationis bull";
var content_f17_49_18195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigoid gestationis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple tense bullae are present on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18195=[""].join("\n");
var outline_f17_49_18195=null;
var title_f17_49_18196="Ergotamine: Pediatric drug information";
var content_f17_49_18196=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ergotamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"    see \"Ergotamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/44/18116?source=see_link\">",
"    see \"Ergotamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ergomar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Blocking Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimigraine Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ergot Alkaloid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"      see \"Ergotamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Not for chronic daily administration: Sublingual: 1 tablet under tongue at first sign, then 1 tablet every 30 minutes; maximum: 3 tablets/24 hours, 5 tablets/week",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual, as tartrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ergomar&reg;: 2 mg [peppermint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sublingual: Place tablet under the tongue; do not crush; may administer without regard to meals",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevent or abort vascular headaches, such as migraine and migraine variants also known as &ldquo;histaminic cephalalgia&rdquo;",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F166348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Absence of pulse, bradycardia, cardiac valvular fibrosis, cyanosis, ECG changes, edema, gangrene, hypertension, ischemia, precordial distress and pain, tachycardia, vasospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Retroperitoneal fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle pain, numbness, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pleuropulmonary fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Cold extremities",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ergotamine or any component; pregnancy; peripheral vascular disease, hepatic or renal disease, hypertension, peptic ulcer disease, sepsis, coronary heart disease; concurrent therapy with potent CYP3A4 inhibitors (eg, protease inhibitors and macrolide antibiotics).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term use is associated with fibrotic changes to heart, pulmonary valves, and rare cases of retroperitoneal fibrosis; chronic usage may also be harmful due to a reduction in cerebral blood flow, ECG changes, and hypertension; sustained vasoconstriction may precipitate angina or MI, aggravate intermittent claudication, or lead to ischemic colitis. Concomitant use with potent inhibitors of CYP3A4 (including protease inhibitors and macrolide antibiotics) has been associated with acute ergot toxicity characterized by serious and/or life-threatening cerebral and peripheral ischemia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; some cases have resulted in amputation; less potent CYP3A4 inhibitors (eg, metronidazole, nefazodone, fluoxetine, zileuton, and azole antifungals) may carry the same risk. Patients who take ergotamine for extended periods of time may become dependent on it and discontinuation may result in withdrawal symptoms (eg, rebound headache). Safety and efficacy have not been established in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Ergotamine. Management: Avoid ergotamine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1058451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid tea, cola, and coffee (caffeine may increase GI absorption of ergotamine). Avoid grapefruit juice; may cause increased blood levels of ergotamine, leading to increased toxicity",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause prolonged constriction of the uterine vessels and/or increased myometrial tone leading to reduced placental blood flow. This has contributed to fetal growth retardation in animals.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha-adrenergic receptors depending upon their site; is a highly active uterine stimulant; it causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, rectal: Erratic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 1.85 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Poor overall (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 0.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In bile as metabolites (90%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/44/18116?source=see_link\">",
"      see \"Ergotamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Any symptoms such as nausea, vomiting, numbness or tingling, and chest, muscle, or abdominal pain should be reported to the physician at the first sign of an attack; do",
"     <b>",
"      not",
"     </b>",
"     exceed recommended dosage; avoid coffee, tea, cola, and grapefruit juice; may cause dry mouth",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13275 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.211.0.116-17E0CDD0BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18196=[""].join("\n");
var outline_f17_49_18196=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708746\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166310\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058443\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058438\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166289\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166275\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058447\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058446\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166348\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058450\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058436\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166339\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166284\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058451\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166286\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166297\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058435\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058449\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058442\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13275\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13275|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=related_link\">",
"      Ergotamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/44/18116?source=related_link\">",
"      Ergotamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_49_18197="Hypertrophic cardiomyopathy";
var content_f17_49_18197=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/49/18197/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/49/18197/contributors\" id=\"au4349\">",
"       William J McKenna, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/49/18197/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/49/18197/contributors\" id=\"se4323\">",
"       Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/49/18197/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/49/18197/contributors\" id=\"de7537\">",
"       Brian C Downey, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?17/49/18197?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HYPERTROPHIC CARDIOMYOPATHY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Hypertrophic cardiomyopathy (HCM) is a genetic disease that causes the heart muscle to become thickened, or hypertrophied. This can impair blood flow into and out from the main pumping chamber of the heart, the left ventricle. In addition, the mitral valve can be affected and may not function properly.",
"    </p>",
"    <p>",
"     Approximately 1 in 500 adults have HCM. It usually causes no symptoms or major problems. In some patients it causes chest pain and shortness of breath, particularly with exercise. In a minority, however, it may cause major limitations and it is the most common cause of sudden cardiac death in people under age 30.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      Normal heart function",
"     </span>",
"     &nbsp;&mdash;&nbsp;The heart is a pump that contains four chambers: the right atrium, right ventricle, left atrium, and left ventricle (",
"     <a class=\"graphic graphic_figure graphicRef77576 \" href=\"UTD.htm?11/14/11495\">",
"      figure 1",
"     </a>",
"     ). Blood returning to the heart from the body flows into the right atrium, and then into the right ventricle. Blood is pumped out of the right ventricle to the lungs, where oxygen is added. Blood then returns to the heart through the left atrium. Blood in the left atrium flows into the left ventricle, which pumps the blood into the aorta to deliver oxygen to the organs and tissues of the body.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HOW DOES HYPERTROPHIC CARDIOMYOPATHY DEVELOP?",
"     </span>",
"    </p>",
"    <p>",
"     Hypertrophic cardiomyopathy is a disorder caused by a \"spelling mistake\" (mutation) in one of a number of different genes, some of which have not yet been identified. The disorder is transmitted as an autosomal dominant trait. This means that there is a 50 percent chance that a parent with HCM will pass the abnormal gene to his or her child. Men and women are equally likely to inherit HCM. However, even if a child is known to have the mutation, the severity of heart disease that will develop cannot be accurately predicted.",
"    </p>",
"    <p>",
"     In hypertrophic cardiomyopathy, the muscular walls of the left ventricle become thickened (",
"     <a class=\"graphic graphic_figure graphicRef50899 \" href=\"UTD.htm?13/46/14053\">",
"      figure 2",
"     </a>",
"     ). As the left ventricular walls thicken, their ability to relax is impaired, causing blood flow into the ventricle to be reduced, like a weight lifter whose muscles may be strong, but stiff.",
"    </p>",
"    <p>",
"     The thickened septum may also cause obstruction of blood from the left ventricle to the aorta by reducing the size of outflow tract so that the mitral valve leaflets contact the septum. This involvement of the mitral valve may prevent the valve from closing completely and allow blood to leak backwards through the opening (known as mitral regurgitation). Other heart-related complications can also develop. (See",
"     <a class=\"local\" href=\"#H14\">",
"      'Hypertrophic cardiomyopathy complications'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      HYPERTROPHIC CARDIOMYOPATHY SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Most patients with hypertrophic cardiomyopathy have no or few symptoms. In some cases, symptoms are only seen with exercise or exertion. Symptoms may first appear during infancy or childhood, although they begin more commonly during puberty, when hypertrophy develops. In a smaller percentage of cases, symptoms may not occur until later in life. If symptoms develop, they may vary in severity from one day to another.",
"    </p>",
"    <p>",
"     The age when symptoms develop, the severity of symptoms, and the long-term prognosis of a person with hypertrophic cardiomyopathy varies. With some mutations there is marked variation between families, but members of the same family are affected more similarly. Some mutations, however, may cause disease within a family that is severe in some people and mild or even absent in others. (See",
"     <a class=\"local\" href=\"#H28\">",
"      'Prognosis'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     The most common symptoms include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Breathlessness (dyspnea) on exertion",
"      </li>",
"      <li>",
"       Breathlessness when lying down that is relieved when sitting or standing (orthopnea)",
"      </li>",
"      <li>",
"       Breathlessness at night that occurs suddenly, often waking the patient (nocturnal dyspnea)",
"      </li>",
"      <li>",
"       Chest pain, which may be caused or worsened by exertion",
"      </li>",
"      <li>",
"       Fainting (syncope) and near-fainting (presyncope)",
"      </li>",
"      <li>",
"       Palpitations, awareness of the heart beat",
"      </li>",
"      <li>",
"       Lightheadedness when sitting or standing up",
"      </li>",
"      <li>",
"       Fatigue or lack of energy",
"      </li>",
"      <li>",
"       Swelling of the legs and feet (edema)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Patients with no or only minor symptoms generally have a better prognosis than those with more severe symptoms. However the severity of symptoms does not necessarily correlate with the extent of cardiac involvement or the risk of sudden death.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Testing for hypertrophic cardiomyopathy may be performed because a person has a family history of the disease or because of a heart murmur, abnormal electrocardiogram (ECG or EKG), or new symptoms. The best first test for HCM is an ECG. However, an echocardiogram is required to confirm the diagnosis. Other tests may also be recommended after the echocardiogram, depending upon the person's symptoms, family history, and echocardiographic findings.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Electrocardiography",
"     </span>",
"     &nbsp;&mdash;&nbsp;An electrocardiogram (ECG or EKG) is a recording of the electrical activity of the heart. It can help determine if there are abnormalities in electrical conduction or thickening or damage to the heart muscle.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Echocardiography",
"     </span>",
"     &nbsp;&mdash;&nbsp;An echocardiogram uses ultrasound (high-frequency sound waves) to measure the thickness and motion of the ventricular walls, the size of the heart's chambers, the function of the heart valves (including the mitral valve), and flow of blood within the heart. Blood flow measurements help to diagnose any left ventricular outflow tract obstruction.",
"    </p>",
"    <p>",
"     Echocardiography is usually performed during rest and may also be performed during or immediately after exercise.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Exercise testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exercise testing determines how the heart performs during activity. The response to exercise is measured by observing symptoms, the heart rhythm, blood pressure, and heart rate as the person walks on a treadmill. The blood pressure and heart rate normally increase during exercise. People with HCM whose blood pressure does not rise with exercise may be at increased risk for sudden cardiac death.",
"    </p>",
"    <p>",
"     Exercise testing may be combined with echocardiography to determine whether left ventricular outflow obstruction develops or worsens during exercise.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Arrhythmia evaluation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Continuous portable (also called ambulatory) monitoring of the ECG can be helpful in identifying rhythm disorders (arrhythmias) in people with hypertrophic cardiomyopathy. One common type of ambulatory monitor is the Holter monitor. This is a small, lightweight, battery operated device that can record a person's ECG for 24 to 48 hours (",
"     <a class=\"graphic graphic_figure graphicRef76605 \" href=\"UTD.htm?38/7/39039\">",
"      figure 3",
"     </a>",
"     ). It is worn at home or at work during routine activities to detect rhythm disorders that may occur sometime during the course of the day.",
"    </p>",
"    <p>",
"     Ambulatory monitoring may identify the cause of symptoms of an irregular heart rhythm, such as heart palpitations, passing out, or feeling lightheaded. Ambulatory monitoring is recommended for all people with HCM to identify abnormal heart rhythms, which may not cause symptoms. (See",
"     <a class=\"local\" href=\"#H21\">",
"      'Arrhythmias'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Arrhythmia evaluation is an important part of the assessment for risk of sudden cardiac death.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Other tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other tests may be recommended during an evaluation for hypertrophic cardiomyopathy, including monitoring for irregular heart rhythms, imaging tests (such as MRI) of the heart, and cardiac catheterization. Testing of family members is recommended in certain situations.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Cardiovascular magnetic resonance",
"     </span>",
"     &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) of the heart (also known as cardiovascular magnetic resonance, CMR) can detect thickening of the left ventricular wall, including portions of the wall than can be difficult to assess by echocardiography. This test may also be helpful in detecting other abnormalities in people with HCM such as leaking of the mitral valve (mitral regurgitation) and scar in the ventricular walls.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Cardiac catheterization",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although echocardiography provides adequate information to assess cardiac function, obstruction and valvular regurgitation in most patients, cardiac catheterization may be indicated in certain patients.",
"    </p>",
"    <p>",
"     In this procedure, catheters (long tubes) are passed through the large blood vessels into the heart to measure pressures and obtain images of the left ventricular chamber. If there is concern that blood vessels of the heart could also be diseased (coronary artery disease), imaging of the coronary arteries (coronary angiography) may also be performed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Evaluation of first-degree relatives",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because hypertrophic cardiomyopathy can be passed from parents to children, evaluation is recommended for all first degree relatives of anyone who is diagnosed with the disease. First degree relatives include siblings and parents.",
"    </p>",
"    <p>",
"     The following are recommendations for evaluation:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A medical history, physical examination, electrocardiography, and echocardiography.",
"      </li>",
"      <li>",
"       Evaluation is not recommended in children younger than 12 years unless the child has symptoms, has a high-risk family history, or the child is participating in intense competitive sports. Thickening of the heart wall often does not appear until adolescence.",
"      </li>",
"      <li>",
"       Evaluation should be repeated once per year from 12 to 18 years of age.",
"      </li>",
"      <li>",
"       Adults (&gt;18 years) with a normal echocardiogram should have screening approximately every five years.",
"      </li>",
"      <li>",
"       Genetic testing for HCM is available, but it is expensive and the results do not always help to determine if and when a person will develop the disease. As a result, genetic testing is not currently recommended in most cases.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      HYPERTROPHIC CARDIOMYOPATHY COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Depending in part upon the severity of disease, some patients with hypertrophic cardiomyopathy develop the following complications:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Heart failure (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"        \"Patient information: Heart failure (Beyond the Basics)\"",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Stroke (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"        \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Rhythm disorder (arrhythmias)",
"      </li>",
"      <li>",
"       Heart block",
"      </li>",
"      <li>",
"       Infection of the heart valve (infective endocarditis)",
"      </li>",
"      <li>",
"       Increased risk of death due to sudden cardiac death, heart failure, or stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      HCM and sudden cardiac death",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people with hypertrophic cardiomyopathy have an increased risk of developing a dangerous heart rhythm (arrhythmia), which can lead to sudden cardiac death (SCD). (See",
"     <a class=\"local\" href=\"#H9\">",
"      'Arrhythmia evaluation'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     In individuals at high risk for sudden cardiac death, an implantable cardioverter-defibrillator (ICD) is recommended to reduce this risk. (See",
"     <a class=\"local\" href=\"#H21\">",
"      'Arrhythmias'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      HYPERTROPHIC CARDIOMYOPATHY TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There is no cure for hypertrophic cardiomyopathy. However, several treatments are available to relieve the symptoms and decrease the risks associated with HCM.",
"    </p>",
"    <p>",
"     Treatment may be recommended to:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Reduce the symptoms of heart failure and chest pain",
"      </li>",
"      <li>",
"       Remove excess muscle from the interventricular septum to improve blood flow",
"      </li>",
"      <li>",
"       Treat abnormal heart rhythms",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       reduce the risk of sudden death",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The optimal treatment depends upon the individual situation. Most people do not have symptoms and do not require any treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Avoidance of dehydration",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with hypertrophic cardiomyopathy should try to maintain a steady fluid balance and avoid situations in which fluid is lost from the body and not adequately replaced (eg, having diarrhea and not drinking adequate fluids).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Activity restriction",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anyone with hypertrophic cardiomyopathy should talk to",
"     <span class=\"nowrap\">",
"      his/her",
"     </span>",
"     healthcare provider about the safety of exercise. Most people with HCM are advised to avoid playing competitive sports, with the possible exception of some low-intensity sports (eg, golf, billiards). Certain recreational sports are also not advised. These recommendations generally apply to all people with HCM.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Shortness of breath and chest pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;One or more medications may be used to treat the symptoms of shortness of breath",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     chest pain. Options include a beta blocker, verapamil,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     disopyramide. These medications work to decrease the heart's need for oxygen, improve the heart's ability to fill with blood, and improve blood flow to the heart.",
"    </p>",
"    <p>",
"     If these treatments do not adequately relieve symptoms and there is significant obstruction to the flow of blood out of the left ventricle (left ventricular outflow tract obstruction), a procedure to reduce the obstruction may be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Arrhythmias",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with hypertrophic cardiomyopathy are at risk for irregular heart rhythms (arrhythmias). Although most arrhythmias do not cause symptoms, some can have serious consequences or even lead to sudden cardiac death. Therefore, testing for arrhythmias is important. (See",
"     <a class=\"local\" href=\"#H9\">",
"      'Arrhythmia evaluation'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     There are two main types of arrhythmias: atrial and ventricular.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Atrial arrhythmias &mdash; The most common atrial arrhythmia is atrial fibrillation (AF). Because AF may cause palpitations, shortness of breath, chest pain, low blood pressure, passing out and risk of stroke, treatment of AF is important. The treatment of AF is discussed separately. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"        \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Ventricular arrhythmias &mdash; There are several types of ventricular arrhythmias, including ventricular premature beats (VPBs), nonsustained ventricular tachycardia (NSVT), sustained ventricular tachycardia (VT), and ventricular fibrillation (VF).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Ventricular premature beats, also known as premature ventricular contractions (PVCs) are not associated with increased risk of sudden cardiac death and do not usually require treatment.",
"      </li>",
"      <li>",
"       NSVT does not itself require treatment, although it is a marker for increased risk of sudden cardiac death.",
"      </li>",
"      <li>",
"       Sustained VT and VF are dangerous arrhythmias that can lead to sudden cardiac death (SCD). People with HCM who have experienced sustained VT or VF, or who are at risk of these rhythms, are advised to have an implantable cardioverter-defibrillator (ICD) to decrease their risk of sudden cardiac death. This therapy is discussed in detail in a separate topic. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"        \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Procedures to relieve left ventricular outflow tract obstruction",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients with hypertrophic cardiomyopathy who are severely symptomatic and who do not improve with medications may be advised to consider septal ablation or surgical treatment, such as myectomy.",
"    </p>",
"    <p>",
"     These procedures are most likely to be successful when performed in a medical center with significant experience in treating people with hypertrophic cardiomyopathy. Assistance in findings such centers can be obtained online at websites for the Hypertrophic Cardiomyopathy Association (",
"     <a class=\"external\" href=\"file://www.4hcm.org/\">",
"      www.4HCM.org",
"     </a>",
"     ) and the Cardiomyopathy Association (",
"     <a class=\"external\" href=\"file://www.cardiomyopathy.org/\">",
"      www.cardiomyopathy.org",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Septal myectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Septal myectomy is the surgical removal of excess muscle from the thickened ventricular septum, the muscular wall between the left and right ventricles. The surgery is performed by opening the chest, placing the person on cardiopulmonary bypass (a heart lung machine), and removing excess tissue in the region of obstruction. Myectomy eliminates or improves symptoms in over 90 percent of patients.",
"    </p>",
"    <p>",
"     When myectomy is performed by an experienced surgeon, the complication rate is low (1 to 2 percent). The most common complication is development of heart block, which sometimes requires treatment with a pacemaker. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"      \"Patient information: Pacemakers (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The mitral valve may be repaired at the time of myectomy if significant mitral regurgitation (leaking of the mitral valve) is present. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=see_link\">",
"      \"Patient information: Mitral regurgitation (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      Nonsurgical septal reduction therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ethanol ablation of the septum, also known as nonsurgical septal reduction therapy (NSRT), or transcoronary ablation of septal hypertrophy (TASH) involves injecting ethanol (alcohol) into the blood vessel supplying the upper part of the thickened septum.",
"    </p>",
"    <p>",
"     In this procedure, a cardiologist inserts an angioplasty catheter into an artery in the groin and threads it up to the base of the aorta (",
"     <a class=\"graphic graphic_figure graphicRef77576 \" href=\"UTD.htm?11/14/11495\">",
"      figure 1",
"     </a>",
"     ). The catheter is passed into the left coronary artery to the branch that supplies the upper part of the septum. A small amount of ethanol is injected into this arterial branch.",
"    </p>",
"    <p>",
"     The ethanol causes death of muscle tissue supplied by the arterial branch, causing the upper part of the septum to become thinner. Thinning of the upper septum reduces obstruction of blood flow from the left ventricle (left ventricular outflow obstruction). The procedure is successful in reducing blockage in 80 to 90 percent of cases.",
"    </p>",
"    <p>",
"     Ethanol ablation should only be performed by an experienced interventional cardiologist in a hospital that has experience caring for people with HCM. Complications are somewhat more common in people who undergo ablation compared to myectomy, with approximately 5 to 25 percent of people developing complete heart block requiring a pacemaker.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Myectomy versus ethanol ablation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although the outcomes with myectomy and ablation are similar, each procedure has its own advantages and disadvantages. Patients should discuss the risks and benefits of each procedure with their healthcare providers.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with hypertrophic cardiomyopathy are generally able to become pregnant and carry the pregnancy without any difficulty. Before becoming pregnant, the woman should speak with her healthcare provider to discuss any potential risks, any medication changes that may be needed, and care during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Management of surgical procedures",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because people with hypertrophic cardiomyopathy have alterations in the heart function, special care may be needed before, during and after surgical procedures to reduce the risk of complications such as heart failure or low blood pressure (hypotension).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The long-term outcome for people with hypertrophic cardiomyopathy is generally good, especially in those who have few or no symptoms and those who are diagnosed later in life. Most people with HCM can live a long life.",
"    </p>",
"    <p>",
"     However some patients with hypertrophic cardiomyopathy are at risk for severe cardiac complications, including heart failure and sudden death. The risk of cardiac complications varies among different families as well as among members within a given family. A major goal of the diagnosis and evaluation process is to identify those patients most likely to develop complications so that appropriate treatment can be provided.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H29\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784898949\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3053334049\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/24/36226?source=see_link\">",
"      Patient information: Hypertrophic cardiomyopathy in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/13/21714?source=see_link\">",
"      Patient information: Dilated cardiomyopathy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/23/39281?source=see_link\">",
"      Patient information: Ventricular premature beats (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/57/3986?source=see_link\">",
"      Patient information: Friedreich ataxia (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3053334114\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=see_link\">",
"      Patient information: Mitral regurgitation (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=see_link\">",
"      Echocardiographic recognition of cardiomyopathies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link\">",
"      Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000192.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000192.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hypertrophic Cardiomyopathy Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.4hcm.org/\">",
"      www.4HCM.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Cardiomyopathy Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cardiomyopathy.org/index.php?id=49\">",
"      www.cardiomyopathy.org/index.php?id=49",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?17/49/18197/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2008.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?17/49/18197?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18197/abstract/1\">",
"      Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation 2008; 117:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18197/abstract/2\">",
"      Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003; 42:1687.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f17_49_18197=[""].join("\n");
var outline_f17_49_18197=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HYPERTROPHIC CARDIOMYOPATHY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HOW DOES HYPERTROPHIC CARDIOMYOPATHY DEVELOP?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           HYPERTROPHIC CARDIOMYOPATHY SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           HYPERTROPHIC CARDIOMYOPATHY COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           HYPERTROPHIC CARDIOMYOPATHY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H29\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/14/11495\" title=\"figure 1\">",
"           Cardiac anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/46/14053\" title=\"figure 2\">",
"           HCM anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/7/39039\" title=\"figure 3\">",
"           Holter monitor PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f17_49_18198="Tofacitinib: Drug information";
var content_f17_49_18198=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tofacitinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/32/7685?source=see_link\">",
"    see \"Tofacitinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F15578463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15673699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xeljanz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15578478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antirheumatic, Disease Modifying;",
"     </li>",
"     <li>",
"      Antirheumatic, Miscellaneous;",
"     </li>",
"     <li>",
"      Janus Associated Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15897300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Rheumatoid arthritis (monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs (DMARDs):",
"     </b>",
"     Oral: 5 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Tofacitinib should not be used in combination with biologic DMARDs or with strong immunosuppressants, such as azathioprine, tacrolimus, or cyclosporine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Dosage adjustment for strong CYP3A4 inhibitors (eg, ketoconazole):",
"     </i>",
"     Reduce dose to 5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustment for concomitant moderate CYP3A4 inhibitors and potent CYP2C19 inhibitors (eg, fluconazole):",
"     </i>",
"     Reduce dose to 5 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15897301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate-to-severe impairment: Reduce dose to 5 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Tofacitinib has not been studied in patients with baseline Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate impairment: Reduce dose to 5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe impairment: Use is not recommended (has not been studied in patients with severe hepatic impairment or in patients with hepatitis B or hepatitis C viruses).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15897302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lymphopenia (lymphocytes &ge;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): Maintain dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lymphopenia (lymphocytes &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): Discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neutropenia (ANC &gt;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): Maintain dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neutropenia (ANC persistently between 500-1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): Interrupt therapy; resume when ANC &gt;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neutropenia (ANC &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): Discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anemia (hemoglobin &ge;9 g/dL",
"     <b>",
"      and",
"     </b>",
"     decrease &le;2 g/dL): Maintain dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anemia (hemoglobin &lt;8 g/dL",
"     <b>",
"      or",
"     </b>",
"     decrease &gt;2 g/dL): Interrupt therapy until hemoglobin values have normalized.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15673700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xeljanz&reg;: 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F15897112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Available through specialty/network pharmacies. Further information may be obtained from the manufacturer, Pfizer Inc, at 1-855-493-5526 or at file://www.xeljanz.com/.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15784558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM330702.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM330702.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15897305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15578467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderately- to severely-active rheumatoid arthritis (as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs [DMARDs]) in patients who have had an inadequate response to, or are intolerant of, methotrexate",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15897183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Percentages noted include the highest frequency regardless of dosage. Frequencies may vary for specific doses; consult prescribing information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Miscellaneous: Infections (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (&gt;3 x upper limit of normal; 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Serum creatinine increased (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infections (5%), nasopharyngitis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Serious infections (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, anemia, dehydration, drug-induced liver injury, dyspepsia, dyspnea, erythema, gastritis, hepatic steatosis, lymphocytopenia, malignancies, musculoskeletal pain, neutropenia, paresthesia, peripheral edema, pruritus, pyrexia, rash, sinus congestion, tendonitis, tuberculosis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15897117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15897118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow suppression:  Lymphocytopenia (after an initial lymphocytosis), neutropenia (&lt;2000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), and anemia have been observed with tofacitinib therapy. Lymphocyte counts &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     were associated with increased incidence of treated and serious infections; avoid tofacitinib initiation in patients with lymphocytes &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     at baseline. Avoid use in patients with ANC &lt;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     at baseline; interrupt therapy if ANC is persistently between 500-1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or if ANC &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     during treatment. Consider resuming tofacitinib when ANC &ge;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Avoid use in patients with hemoglobin &lt;9 g/dL; interrupt therapy if hemoglobin decreases &gt;2 g/dL or if hemoglobin &lt;8 g/dL. Monitor lymphocyte counts at baseline and every 3 months thereafter; ANC, platelet counts, and hemoglobin should be assessed at baseline, after 4-8 weeks of therapy, and every 3 months thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal perforations: Use with caution in patients at increased risk for gastrointestinal perforation (eg, history of diverticulitis); perforations have been reported in clinical trials. Promptly evaluate new-onset abdominal symptoms in patients taking tofacitinib.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: Increased incidence of liver enzyme elevation was observed in patients taking tofacitinib compared to placebo. Routine liver function test monitoring is recommended; interrupt therapy if drug-induced liver injury is suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Patients receiving tofacitinib are at increased risk for serious infections, which may result in hospitalization and/or fatality; infections often developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate or corticosteroids) and may present as disseminated disease. Active tuberculosis (disseminated or extrapulmonary), invasive fungal (including cryptococcosis and pneumocystosis) and bacterial, viral or other opportunistic infections (including esophageal candidiasis, multidermatomal herpes zoster, cytomegalovirus, and BK virus) have been reported in patients receiving tofacitinib.",
"     </b>",
"     Reactivation of viral infections (eg, herpes zoster) was observed in clinical trials; the incidence of chronic viral hepatitis reactivation is unknown. Use with caution in patients that have been exposed to tuberculosis, with a history of serious or opportunistic infection, taking concomitant immunosuppressants, with comorbid conditions that predispose them to infections (eg, diabetes), or in patients who live in or travel to/from areas of endemic mycoses (ie, blastomycosis, coccidioidomycosis, histoplasmosis). Consider risks versus benefits prior to use in patients with a history of chronic or recurrent infection; do not initiate tofacitinib in patients with active infections, including localized infections. Monitor closely for signs/symptoms of infection during therapy; interrupt therapy if serious infections or sepsis develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lipid abnormalities: Increases in lipid parameters (eg, total cholesterol, LDL, and HDL cholesterol) were observed in patients receiving tofacitinib; maximum lipid increases were typically seen within 6 weeks of initiation. Assess lipids 4-8 weeks after tofacitinib initiation and manage lipid abnormalities accordingly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Lymphoma and other malignancies have been reported in patients receiving tofacitinib; Epstein Barr Virus-associated post-transplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients receiving tofacitinib and concomitant immunosuppressive medications.",
"     </b>",
"     The most common types of malignancy observed were lung, breast, gastric, colorectal, renal cell, prostate, lymphoma, and malignant melanoma. Consider risks versus benefits prior to use in patients with a known malignancy (other than successfully treated nonmelanoma skin cancers [NMSC]) or when continuing tofacitinib in patients who develop a new malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Tuberculosis:",
"     <b>",
"      [U.S. Boxed Warning]: Tuberculosis (disseminated or extrapulmonary) has been reported in patients receiving tofacitinib. Patients should be evaluated for tuberculosis risk factors and active or latent infection (with a tuberculin skin test) before and during therapy. Treatment of latent tuberculosis should be initiated before use. Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis throughout treatment;",
"     </b>",
"     active tuberculosis has developed in this population during treatment with tofacitinib. Use with caution in patients who have resided in regions where tuberculosis is endemic. Consider antituberculosis therapy if an adequate course of treatment cannot be confirmed in patients with a history of latent or active tuberculosis or for patients with risk factors despite negative skin test.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use is not recommended in patients with severe hepatic impairment; dosage reduction required in patients with moderate hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Dosage reduction required in patients with moderate or severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunosuppressant medications: Tofacitinib should not be administered in combination with strong immunosuppressive medications (eg, azathioprine, tacrolimus, cyclosporine) due to the risk of additive immunosuppression; such combinations have not been studied in rheumatoid arthritis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Biologic DMARDs: Tofacitinib should not be administered in combination with biologic DMARDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use with caution in elderly patients; general incidence of infection is higher in elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunizations: Immunization status should be current before initiating therapy. Live vaccines should not be given concomitantly with tofacitinib; no data are available concerning vaccination response or secondary transmission of infection by live vaccines in patients receiving therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15977374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15977370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: May enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: May enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-TNF Agents: May enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tofacitinib. Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Tofacitinib. Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving moderate CYP3A4 inhibitors that strongly inhibit CYP2C19 (e.g., fluconazole, sitaxentan).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the immunosuppressive effect of Tofacitinib. Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: May enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sitaxentan: May increase the serum concentration of Tofacitinib. Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving moderate CYP3A4 inhibitors that strongly inhibit CYP2C19 (e.g., fluconazole, sitaxentan).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15897113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15897114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Healthcare providers are encouraged to enroll women exposed to tofacitinib during pregnancy in the Xeljanz&reg; Pregnancy Registry (877-311-8972); patients may also enroll themselves.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15897115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15897116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tofacitinib is excreted into breast milk. Due to the potential for adverse reactions in a nursing infant, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Xeljanz Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (60): $2466.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15897313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lymphocyte count (baseline and every 3 months thereafter); neutrophil/platelet counts (baseline, after 4-8 weeks, and every 3 months thereafter); lipids (4-8 weeks after therapy initiation and periodically); hemoglobin (baseline, after 4-8 weeks, and every 3 months thereafter); LFTs; signs/symptoms of infections (including tuberculosis) during and after therapy; abdominal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15897248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tofacitinib inhibits Janus kinase (JAK) enzymes, which are intracellular enzymes involved in stimulating hematopoiesis and immune cell function through a signaling pathway. In response to extracellular cytokine or growth factor signaling, JAKs activate signal transducers and activators of transcription (STATs), which regulate gene expression and intracellular activity. Inhibition of JAKs prevents cytokine- or growth factor-mediated gene expression and intracellular activity of immune cells, reduces circulating CD16/56+ natural killer cells, serum IgG, IgM, IgA, and C-reactive protein, and increases B cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15897250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Rapid (74%); C",
"     <sub>",
"      max",
"     </sub>",
"     is reduced by 32% when administered with high-fat meal, but AUC remains unchanged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 87 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~40% (predominantly to albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic (70%): CYP3A4 and CYP2C19 to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Primarily urine (30%) as unchanged drug",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87040 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18198=[""].join("\n");
var outline_f17_49_18198=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15578463\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673699\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15578478\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897300\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897301\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897303\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897304\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897302\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673700\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897112\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15784558\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897305\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15578467\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897183\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897117\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897118\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15977374\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15977370\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897113\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897114\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897115\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897116\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570460\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897313\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897248\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897250\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87040\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87040|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/32/7685?source=related_link\">",
"      Tofacitinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_49_18199="Eclipse nevus";
var content_f17_49_18199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eclipse nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A compound nevus on the scalp of a child showing a light brown center and a more intensely pigmented rim.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18199=[""].join("\n");
var outline_f17_49_18199=null;
var title_f17_49_18200="Epidemiology, natural history, and diagnosis of actinic keratosis";
var content_f17_49_18200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, natural history, and diagnosis of actinic keratosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/49/18200/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/49/18200/contributors\">",
"     R Steven Padilla, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/49/18200/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/49/18200/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/49/18200/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/49/18200/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/49/18200/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17075246\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Actinic keratosis (AK, also known as solar keratosis) is a cutaneous lesion that results from the proliferation of atypical epidermal keratinocytes. AKs represent early lesions on a continuum with squamous cell carcinoma (SCC) and occasionally progress to SCC.",
"   </p>",
"   <p>",
"    AKs often present as erythematous and scaly macules or papules; lesions are most commonly detected in adults with fair skin. Chronic sun exposure is a major risk factor for the development of these lesions, which accounts for the usual detection of AKs in frequently sun-exposed areas (eg, balding scalp, face, lateral neck, and distal upper or lower extremities).",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, natural history, and diagnosis of AK will be discussed here. The management of AK and SCC is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30968?source=see_link\">",
"     \"Treatment of actinic keratosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17075254\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, AKs are among the most common reasons for visits to dermatologists [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. It is estimated that between 1990 and 1999, 14 percent of dermatology visits in the United States were related to AKs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with fair skin are most likely to develop AKs, and much of the data on the epidemiology and risk factors for AK are derived from studies in Australia, northern Europe, and the United States. Factors such as the extent of exposure to ultraviolet light and certain phenotypic features have been associated with risk for developing these lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624955\">",
"    <span class=\"h2\">",
"     Ultraviolet radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraviolet radiation is believed to contribute to the development of AK through the induction of mutations in epidermal keratinocytes that lead to increased survival and proliferation of atypical cells [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/5\">",
"     5",
"    </a>",
"    ]. Mutations in the p53 tumor suppressor gene, a gene involved in cell cycle regulation, apoptosis, and DNA repair, have been detected in 30 to 50 percent of lesional skin samples from patients with AKs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H584300\">",
"    <span class=\"h3\">",
"     Extent of sun exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with extensive sun exposure, such as those with outdoor occupations, are at increased risk for AK [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In a population-based study of 20,637 people in the United States, AKs were present in 55 percent of white men and 37 percent of white women between the ages of 65 and 74 years and who were classified as having high cumulative sun exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast, among a similar demographic population composed of subjects with low cumulative exposure to the sun, AKs were present in only 19 percent of men and 12 percent of women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H584307\">",
"    <span class=\"h3\">",
"     History of sunburn",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of sunburn increases the risk for AK [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In an Australian study of 2045 residents of Queensland, Australia (aged 20 to 69 years), six or more painful sunburns over the course of life were associated with an increased likelihood for AK (prevalence odds ratio [OR] 1.47, 95% CI 1.01-2.14) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/9\">",
"     9",
"    </a>",
"    ]. A separate cohort study of 197 residents of the same Australian state found that even a single episode of sunburn in childhood elevated the risk for AK [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=see_link\">",
"     \"Sunburn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H584314\">",
"    <span class=\"h3\">",
"     Impact of sun protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stimulatory role of sun exposure on the development of AKs is supported by evidence that use of sunscreens reduces the development of these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In a seven-month randomized trial, 588 residents (aged 40 or older) of Victoria, Australia who had between 1 and 30 AKs were instructed to apply either a broad-spectrum sunscreen with a sun protection factor (SPF) of 17 or a vehicle cream to the head, neck, and forearms daily. Patients in the sunscreen group developed significantly fewer new AKs (mean number of new lesions 1.6 versus 2.3) and had significantly more spontaneous remissions of AKs (mean percentage of resolved lesions 28 versus 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/12\">",
"     12",
"    </a>",
"    ]. The 157 subjects who withdrew from the study prior to completion were not included in the study analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H29#H29\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Protection from sun exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624970\">",
"    <span class=\"h2\">",
"     Phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin color contributes to the risk for AK, as the majority of AKs are detected in individuals with fair skin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/8-11,14,15\">",
"     8-11,14,15",
"    </a>",
"    ]. Epidermal melanin absorbs ultraviolet radiation and shields keratinocytes against damage from ultraviolet light, resulting in a reduced risk for AK with darkening skin pigmentation.",
"   </p>",
"   <p>",
"    The importance of skin color is supported by a study of 197 residents of Queensland, Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/10\">",
"     10",
"    </a>",
"    ]. Compared with olive-skinned individuals, people with fair or medium-toned (between fair and olive) skin were significantly more likely to develop AKs (age and sex adjusted odds ratios [OR] of 14.1, 95% CI 2.9-69.6 and 6.5, 95% CI 1.2-34.7, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, AKs are uncommon in African-Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/11\">",
"     11",
"    </a>",
"    ]. Freckling, light hair color, a propensity to sunburn easily, and an inability to tan, which are more often seen in people with fair skin, are additional features that have been associated with increased risk for AK [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/1,11\">",
"     1,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H422395\">",
"    <span class=\"h2\">",
"     Gender, age, and geographic location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex and age influence the risk for AK. Men are more likely than women to develop these lesions, and the prevalence of AK rises with age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/9,14,16-18\">",
"     9,14,16-18",
"    </a>",
"    ]. The magnitude of these effects is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study in Queensland, Australia that evaluated the prevalence of AK in 2045 adults between the ages of 20 and 69 years, AKs were detected in 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/9\">",
"       9",
"      </a>",
"      ]. Lesions were present in 79 percent of men and 68 percent of women between the ages of 60 and 69 compared with only 10 percent of men and 5 percent of women aged 20 to 29 years.",
"     </li>",
"     <li>",
"      A cohort study of 1040 people over the age of 40 in North Central Victoria, Australia also detected a high prevalence of AK that increased with age. Fifty-nine percent of study participants had at least one AK, and the mean age of individuals with AK was significantly higher than in those without AK (62 versus 54 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared with Australia, AKs are less prevalent in the United States and northern Europe, where there is generally less sun exposure. Estimates of the proportion of adults with AKs in these locations range from 11 to 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/1,16,18,19\">",
"     1,16,18,19",
"    </a>",
"    ]. The impact of geographic location was illustrated in a cohort study that compared the prevalence of AKs in Australian-born adults with that in British immigrants to Australia. All subjects were age 40 years or older. The prevalence of AKs in those who immigrated to Australia before the age of 20 became similar to native Australians in late adulthood, while those who immigrated after the age of 20 had fewer AKs than native Australians in all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/20\">",
"     20",
"    </a>",
"    ]. These results suggest that living in a location associated with greater exposure to ultraviolet light early in life may increase the risk for AK.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421852\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H584493\">",
"    <span class=\"h3\">",
"     Genetic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with genetic disorders that interfere with effective DNA repair after exposure to ultraviolet radiation are at increased risk for AK. Examples include xeroderma pigmentosum, Bloom syndrome, and Rothmund-Thompson syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H523750964#H523750964\">",
"     \"The genodermatoses\", section on 'Xeroderma pigmentosum'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35493?source=see_link\">",
"     \"Bloom syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624962\">",
"    <span class=\"h3\">",
"     Human papillomavirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Betapapillomavirus types of human papillomavirus (HPV) have been detected in AKs, squamous cell carcinomas (SCC), and basal cell carcinomas (BCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/14,21-25\">",
"     14,21-25",
"    </a>",
"    ]. However, HPV is also detected in normal skin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/23\">",
"     23",
"    </a>",
"    ], and an etiologic relationship between HPV and these lesions is uncertain. A cohort study of 291 adults (ages 36 to 86 years) in Queensland, Australia who were tested for the presence of betapapillomavirus in eyebrow hairs in 1996 did not identify an independent association of betapapillomavirus infection with the detection of AK in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/14\">",
"     14",
"    </a>",
"    ]. However, when combined with risk factors for AKs (eg, fair skin, male sex, age over 60), betapapillomavirus infection appeared to increase the likelihood for the development of AK. Additional studies are necessary to explore the role of HPV in this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421788\">",
"    <span class=\"h3\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression has been associated with increased risk for SCC and may also increase risk for AK [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In a study of 94 renal transplant recipients in England (mean age 38 years and mean duration from transplant 4.5 years) and their matched controls, AKs developed in seven of the transplant recipients (7.4 percent) and in none of the controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/27\">",
"     27",
"    </a>",
"    ]. All patients with AKs had a history of high sun exposure, defined as more than three months in a tropical or subtropical climate or more than five years in an outdoor occupation. The risk for AK may rise as the time interval after transplant increases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/26,28\">",
"     26,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17075261\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKs typically develop as solitary or multiple lesions on highly sun exposed areas, such as the balding scalp, neck, dorsal hands, and dorsal forearms. The lower extremities are an additional common site for AKs in women. Skin adjacent to AKs usually shows signs of solar damage, such as a yellow or pale color, spotty hyperpigmentation, scattered telangiectasias, or xerosis. AKs are generally asymptomatic, but some patients experience local tenderness or a stinging sensation.",
"   </p>",
"   <p>",
"    AKs present as several clinical variants, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Classic (common) &ndash;",
"      </strong>",
"      The classic form of AK presents as an erythematous, scaly macule, papule, or plaque (",
"      <a class=\"graphic graphic_picture graphicRef50949 graphicRef53177 \" href=\"UTD.htm?11/29/11737\">",
"       picture 1A-B",
"      </a>",
"      ). Lesions typically range from a few millimeters to 2 cm in diameter. Occasionally, lesions are larger.",
"     </li>",
"     <li>",
"      <strong>",
"       Hypertrophic &ndash;",
"      </strong>",
"      Hypertrophic AKs are characterized by the presence of thick, adherent scale on an erythematous base (",
"      <a class=\"graphic graphic_picture graphicRef63461 graphicRef72634 \" href=\"UTD.htm?13/34/13865\">",
"       picture 2A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Atrophic &ndash;",
"      </strong>",
"      Scale is absent in atrophic AKs. Lesions are smooth, red macules.",
"     </li>",
"     <li>",
"      <strong>",
"       AK with cutaneous horn",
"      </strong>",
"      &ndash; A cutaneous horn is a keratotic projection the height of which is at least one-half of the largest diameter (",
"      <a class=\"graphic graphic_picture graphicRef50667 \" href=\"UTD.htm?18/26/18852\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/29\">",
"       29",
"      </a>",
"      ]. The mound of compact keratin often resembles a spicule or cone. Several other skin lesions can present with cutaneous horns. (See",
"      <a class=\"local\" href=\"#H625191\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Pigmented &ndash;",
"      </strong>",
"      Pigmented actinic keratoses usually present as scaly, hyperpigmented macules or patches. Lesions may be large, exceeding 1.5 cm in some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/15\">",
"       15",
"      </a>",
"      ]. Pigmented AKs can be difficult to distinguish from lentigo maligna. (See",
"      <a class=\"local\" href=\"#H625191\">",
"       'Differential diagnosis'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H625426\">",
"       'Dermoscopy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Actinic cheilitis &ndash;",
"      </strong>",
"      Actinic cheilitis (also known as solar cheilosis) is a term that is used to refer to lesions analogous to AKs that occur on the lip [",
"      <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/30\">",
"       30",
"      </a>",
"      ]. This disorder typically presents on the lower lip as a persistent rough or scaly area (",
"      <a class=\"graphic graphic_picture graphicRef68057 graphicRef67012 graphicRef79589 \" href=\"UTD.htm?5/21/5466\">",
"       picture 4A-C",
"      </a>",
"      ). Patients often complain of a constantly dry lip. Actinic cheilitis may involve only a small portion of the lip or the entire lower lip. Fissuring or ulceration may also occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17075268\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKs are increasingly considered lesions that are on a continuum with squamous cell carcinoma (SCC) rather than lesions that are distinct from SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/31\">",
"     31",
"    </a>",
"    ]. This viewpoint recognizes the potential for AKs to progress to invasive skin cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H422059\">",
"    <span class=\"h2\">",
"     Progression to skin cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of progression of an individual AK to SCC is low. Estimates of annual rates of transformation have ranged from 0.03 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. The following data come from two of the largest studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An Australian study that evaluated 1689 adults over the age of 40 who had more than 20,000 AKs found the risk for transformation of an individual AK to SCC within one year to be less than 0.1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Analysis of data from a cohort of patients in a United States trial designed to investigate the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"       topical tretinoin",
"      </a>",
"      for skin cancer prevention in patients with at least two prior keratinocyte carcinomas revealed a rate of transformation to invasive or in situ SCC of 0.6 percent in 6015 AKs followed for one year and a rate of 2.6 percent in 1480 lesions followed for four years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Progression of AKs to basal cell carcinoma (BCC) occurred in 0.5 percent of AKs within one year and in 1.6 percent within four years. However, it is unclear whether this finding was related the misdiagnosis of early BCCs as AKs or was true disease progression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although few AKs progress to SCC, data from these studies suggest that approximately 60 percent of cutaneous SCCs arise from preexisting AKs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This observation supports a close relationship between these lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H422105\">",
"    <span class=\"h2\">",
"     Spontaneous resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions that do not progress to SCC may regress or persist as AKs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/17,33,36\">",
"     17,33,36",
"    </a>",
"    ]. Analysis of the same cohort of patients from the tretinoin chemopreventive trial mentioned above revealed that 55 percent of untreated AKs clinically regressed within one year and 70 percent were no longer present at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625576\">",
"    <span class=\"h2\">",
"     Risk for skin cancer in other sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of AKs do not progress to SCC, the presence of AKs serves as a marker of chronic sun damage and, therefore, of an increased risk for the development of both SCC and BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17075275\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AK is frequently diagnosed clinically through a combination of touch and visual inspection. Some macular lesions lack erythema and are more easily identified through the detection of rough texture. Lesion biopsy is performed if the diagnosis is uncertain. A common indication for biopsy is the differentiation of AK from squamous cell carcinoma (SCC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625191\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinguishing AK from SCC can be challenging, as both disorders commonly present as erythematous, scaly papules on sun exposed areas. Lesions with underlying substance, or that are tender, ulcerated, or rapidly growing, are particularly suspicious for SCC. Such lesions should be biopsied for definitive diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to SCC, multiple other lesions may resemble AKs. Classic (common) AKs may resemble:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SCC (",
"      <a class=\"graphic graphic_picture graphicRef64981 \" href=\"UTD.htm?39/26/40358\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Benign lichenoid keratoses (",
"      <a class=\"graphic graphic_picture graphicRef73523 \" href=\"UTD.htm?10/56/11143\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Superficial basal cell carcinoma (",
"      <a class=\"graphic graphic_picture graphicRef57990 \" href=\"UTD.htm?16/50/17188\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inflamed seborrheic keratosis (",
"      <a class=\"graphic graphic_picture graphicRef74039 \" href=\"UTD.htm?12/18/12582\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Porokeratosis (",
"      <a class=\"graphic graphic_picture graphicRef81874 graphicRef62258 \" href=\"UTD.htm?16/26/16809\">",
"       picture 9A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inflammatory dermatoses (psoriasis, seborrheic dermatitis) (",
"      <a class=\"graphic graphic_picture graphicRef64836 graphicRef82073 graphicRef56410 \" href=\"UTD.htm?8/22/8554\">",
"       picture 10A-C",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypertrophic AKs or AK with cutaneous horn may resemble:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SCC (",
"      <a class=\"graphic graphic_picture graphicRef74240 \" href=\"UTD.htm?24/63/25587\">",
"       picture 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Viral wart (",
"      <a class=\"graphic graphic_picture graphicRef78884 \" href=\"UTD.htm?9/17/9488\">",
"       picture 12",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Seborrheic keratosis (",
"      <a class=\"graphic graphic_picture graphicRef59020 \" href=\"UTD.htm?15/40/16015\">",
"       picture 13",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pigmented AKs share clinical features with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Seborrheic keratosis (often distinguished by a &ldquo;stuck on&rdquo; appearance) (",
"      <a class=\"graphic graphic_picture graphicRef64738 \" href=\"UTD.htm?23/3/23606\">",
"       picture 14",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Solar lentigo (",
"      <a class=\"graphic graphic_picture graphicRef61452 \" href=\"UTD.htm?6/10/6306\">",
"       picture 15",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lentigo maligna melanoma (",
"      <a class=\"graphic graphic_picture graphicRef74664 \" href=\"UTD.htm?17/50/18211\">",
"       picture 16",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1503601\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision of whether to perform a biopsy is determined by certainty of diagnosis. In particular, biopsy to rule out SCC should be considered for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lesions greater than 1 cm in diameter",
"     </li>",
"     <li>",
"      Lesions with underlying",
"      <span class=\"nowrap\">",
"       substance/induration",
"      </span>",
"     </li>",
"     <li>",
"      Rapidly growing lesions",
"     </li>",
"     <li>",
"      Ulcerated lesions",
"     </li>",
"     <li>",
"      Tender lesions",
"     </li>",
"     <li>",
"      Lesions that fail to respond to appropriate therapy (eg, AK that persists 8 to 12 weeks after treatment with liquid nitrogen)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625412\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsies of lesions suspicious for AK are most commonly performed with a shave or punch biopsy technique. If only a portion of the lesion can be removed due to size or concern for scarring, the thickest area of the lesion should be biopsied as SCC arising in an AK is most likely to be detected in this area.",
"   </p>",
"   <p>",
"    Shave biopsies should extend into the dermis, and preferably at least into the mid-reticular dermis for lesions that are suspicious for SCC. An insufficient biopsy depth will compromise the pathologist&rsquo;s ability to rule out an invasive SCC. Punch biopsies performed with the full length of the punch blade usually reach the subcutaneous fat. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H5#H5\">",
"     \"Skin biopsy techniques\", section on 'Biopsy techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625419\">",
"    <span class=\"h3\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic findings of AKs are dependent upon the clinical variant and specific lesion characteristics. Unlike invasive SCCs, atypical keratinocytes do not invade into the dermis. Common histopathologic features of AK include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A collection of",
"      <strong>",
"       atypical keratinocytes",
"      </strong>",
"      with hyperchromatic and pleomorphic nuclei that extends from the basal layer of the epidermis upward; the full thickness of the epidermis is spared (",
"      <a class=\"graphic graphic_picture graphicRef76208 graphicRef54208 \" href=\"UTD.htm?38/20/39241\">",
"       picture 17A-B",
"      </a>",
"      ). Mitoses are not uncommon, and acanthosis (epidermal thickening) may be present.",
"     </li>",
"     <li>",
"      A hyperkeratotic stratum corneum with alternating areas of",
"      <strong>",
"       orthokeratosis and parakeratosis",
"      </strong>",
"      (&ldquo;flag sign&rdquo;), particularly in hypertrophic AKs",
"     </li>",
"     <li>",
"      A variable",
"      <strong>",
"       lymphocytic dermal infiltrate",
"      </strong>",
"     </li>",
"     <li>",
"      Dermal changes consistent with",
"      <strong>",
"       solar elastosis",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the above, pigmented AKs demonstrate increased melanin in the lower epidermis and dermal melanophages. Clinically atrophic lesions demonstrate a thin epidermis with atypia that predominantly involves the basal layer.",
"   </p>",
"   <p>",
"    Histologic variants of AK include bowenoid, lichenoid, and acantholytic subtypes. The existence of the histologic bowenoid variant of AK is controversial. Bowenoid AKs are characterized by full-thickness epidermal dysplasia that is indistinguishable from SCC in situ; notably, keratinocytes in the acrosyringium are spared. Lichenoid lesions feature vacuolization of the basal layer of the epidermis and a band-like chronic inflammatory infiltrate in the superficial dermis. Acantholytic AKs exhibit detachment of keratinocytes due to loss of intercellular bridges; this results in the formation of clefts or lacunae immediately above the basal layer.",
"   </p>",
"   <p>",
"    A histologic grading system analogous to that used for cervical intraepithelial neoplasia in gynecology has been proposed for AKs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/40\">",
"     40",
"    </a>",
"    ]. In this system, the term keratinocytic intraepidermal neoplasia, divided into grades of I, II, and III, is used to describe the progression AK to in situ SCC. This grading system has not been widely adopted.",
"   </p>",
"   <p>",
"    Biopsy specimens should be sent to a dermatopathologist when feasible. If pathology results fail to correlate with the clinical findings, consultation with the dermatopathologist may be beneficial. Additional pathologic sections may aid in identifying an invasive SCC, particularly in cases in which clinical suspicion for SCC is high [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625426\">",
"    <span class=\"h2\">",
"     Dermoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermoscopy is a noninvasive procedure that involves use of a handheld tool that combines magnification and a transilluminating light source to aid in the diagnosis of many cutaneous lesions. Dermoscopy is widely used for the evaluation of melanocytic nevi and lesions suspicious for melanoma.",
"   </p>",
"   <p>",
"    Common dermoscopic features of nonpigmented AKs include a strawberry pattern (background erythema or a red pseudonetwork that consists of unfocused large vessels between hair follicles and prominent follicular openings surrounded by white halos) or a vascular pattern with linear, wavy vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/42\">",
"     42",
"    </a>",
"    ]. Pigmented AKs commonly demonstrate slate-gray to brown dots and globules around follicular ostia and annular-granular and rhomboidal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical practice, distinguishing between pigmented AKs and lentigo maligna can be challenging. Dermoscopy may not be reliable for distinguishing between these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18200/abstract/43\">",
"     43",
"    </a>",
"    ], and histopathologic examination remains the gold standard for such cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/8/19586?source=see_link\">",
"       \"Patient information: Actinic keratosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34235306\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Actinic keratoses (AKs) are common cutaneous lesions that result from the proliferation of atypical epidermal keratinocytes. Major risk factors for the development of AKs include chronic sun exposure, fair skin, advancing age, and male sex. (See",
"      <a class=\"local\" href=\"#H17075246\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17075254\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AKs most commonly present as scaly, erythematous macules or papules on sites of chronic sun exposure (",
"      <a class=\"graphic graphic_picture graphicRef50949 graphicRef53177 \" href=\"UTD.htm?11/29/11737\">",
"       picture 1A-B",
"      </a>",
"      ). Lesions may also be pigmented, nonerythematous, or free of scale. Typical locations for AKs include the scalp, face, lateral neck, dorsal forearms, and dorsal hands. Actinic cheilitis is a variant of AK that involves the lip (",
"      <a class=\"graphic graphic_picture graphicRef68057 graphicRef67012 graphicRef79589 \" href=\"UTD.htm?5/21/5466\">",
"       picture 4A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17075261\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AKs may progress to squamous cell carcinoma (SCC). The risk that an individual AK will progress is low, but approximately 60 percent of cutaneous SCCs arise in sites of preexisting AKs. In addition, patients with AKs are at increased risk for the development of SCCs or BCCs in other sites. (See",
"      <a class=\"local\" href=\"#H17075268\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of AK is often made based on visual and tactile clinical inspection. Biopsy is indicated if the diagnosis is uncertain; a common indication for biopsy is distinguishing AK from SCC. In particular, lesions that are greater than 1 cm in diameter, indurated, ulcerated, or rapidly growing and lesions that fail to respond to appropriate therapy should be considered for biopsy. (See",
"      <a class=\"local\" href=\"#H17075275\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pigmented AKs are often difficult to distinguish from lentigo maligna on clinical exam. Histopathologic examination is the gold standard for diagnosis. Dermoscopy may not reliably distinguish between these lesions. (See",
"      <a class=\"local\" href=\"#H625426\">",
"       'Dermoscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/1\">",
"      Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/2\">",
"      Feldman SR, Fleischer AB Jr, McConnell RC. Most common dermatologic problems identified by internists, 1990-1994. Arch Intern Med 1998; 158:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/3\">",
"      Gupta AK, Cooper EA, Feldman SR, Fleischer AB Jr. A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. National Ambulatory Medical Care Survey. Cutis 2002; 70:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/4\">",
"      Warino L, Tusa M, Camacho F, et al. Frequency and cost of actinic keratosis treatment. Dermatol Surg 2006; 32:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/5\">",
"      Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol 2000; 42:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/6\">",
"      Taguchi M, Watanabe S, Yashima K, et al. Aberrations of the tumor suppressor p53 gene and p53 protein in solar keratosis in human skin. J Invest Dermatol 1994; 103:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/7\">",
"      Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 1994; 85:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/8\">",
"      Hensen P, M&uuml;ller ML, Haschemi R, et al. Predisposing factors of actinic keratosis in a North-West German population. Eur J Dermatol 2009; 19:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/9\">",
"      Green A, Beardmore G, Hart V, et al. Skin cancer in a Queensland population. J Am Acad Dermatol 1988; 19:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/10\">",
"      Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol 1998; 139:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/11\">",
"      Engel A, Johnson ML, Haynes SG. Health effects of sunlight exposure in the United States. Results from the first National Health and Nutrition Examination Survey, 1971-1974. Arch Dermatol 1988; 124:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/12\">",
"      Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/13\">",
"      Ulrich C, J&uuml;rgensen JS, Degen A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161 Suppl 3:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/14\">",
"      McBride P, Neale R, Pandeya N, Green A. Sun-related factors, betapapillomavirus, and actinic keratoses: a prospective study. Arch Dermatol 2007; 143:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/15\">",
"      Goldberg LH, Mamelak AJ. Review ofactinic keratosis. Part I: etiology, epidemiology and clinical presentation. J Drugs Dermatol 2010; 9:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/16\">",
"      Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/17\">",
"      Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/18\">",
"      Zagula-Mally ZW, Rosenberg EW, Kashgarian M. Frequency of skin cancer and solar keratoses in a rural southern county as determined by population sampling. Cancer 1974; 34:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/19\">",
"      Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994; 131:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/20\">",
"      Marks R, Jolley D, Lectsas S, Foley P. The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med J Aust 1990; 152:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/21\">",
"      Pfister H, Fuchs PG, Majewski S, et al. High prevalence of epidermodysplasia verruciformis-associated human papillomavirus DNA in actinic keratoses of the immunocompetent population. Arch Dermatol Res 2003; 295:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/22\">",
"      Astori G, Lavergne D, Benton C, et al. Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. J Invest Dermatol 1998; 110:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/23\">",
"      Forslund O, Ly H, Reid C, Higgins G. A broad spectrum of human papillomavirus types is present in the skin of Australian patients with non-melanoma skin cancers and solar keratosis. Br J Dermatol 2003; 149:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/24\">",
"      Weissenborn SJ, Nindl I, Purdie K, et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol 2005; 125:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/25\">",
"      Forslund O, Lindel&ouml;f B, Hradil E, et al. High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in \"Stripped\" biopsies from the same tumors. J Invest Dermatol 2004; 123:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/26\">",
"      Keller B, Braathen LR, Marti HP, Hunger RE. Skin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern. Swiss Med Wkly 2010; 140:w13036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/27\">",
"      Boyle J, MacKie RM, Briggs JD, et al. Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet 1984; 1:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/28\">",
"      Chen QP, Aw DC. Epidemiology of skin diseases in renal transplant recipients in a tertiary hospital. Ann Acad Med Singapore 2010; 39:904.",
"     </a>",
"    </li>",
"    <li>",
"     Duncan KO, Geisse JK, Leffell DJ. Epithelial precancerous lesions. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al.  (Eds), McGraw-Hill, 2008. Vol 1, p.1007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/30\">",
"      Jadotte YT, Schwartz RA. Solar cheilosis: an ominous precursor: part I. Diagnostic insights. J Am Acad Dermatol 2012; 66:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/31\">",
"      Padilla RS, Sebastian S, Jiang Z, et al. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol 2010; 146:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/32\">",
"      Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/33\">",
"      Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/34\">",
"      Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006; 16:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/35\">",
"      Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 2007; 33:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/36\">",
"      Harvey I, Frankel S, Marks R, et al. Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/37\">",
"      Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer 1990; 46:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/38\">",
"      Marks R, Rennie G, Selwood T. The relationship of basal cell carcinomas and squamous cell carcinomas to solar keratoses. Arch Dermatol 1988; 124:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/39\">",
"      Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/40\">",
"      Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma (\"actinic keratosis\"). J Am Acad Dermatol 2000; 42:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/41\">",
"      Carag HR, Prieto VG, Yballe LS, Shea CR. Utility of step sections: demonstration of additional pathological findings in biopsy samples initially diagnosed as actinic keratosis. Arch Dermatol 2000; 136:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/42\">",
"      Peris K, Micantonio T, Piccolo D, Fargnoli MC. Dermoscopic features of actinic keratosis. J Dtsch Dermatol Ges 2007; 5:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18200/abstract/43\">",
"      Akay BN, Kocyigit P, Heper AO, Erdem C. Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna. Br J Dermatol 2010; 163:1212.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13712 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18200=[""].join("\n");
var outline_f17_49_18200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34235306\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17075246\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17075254\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H624955\">",
"      Ultraviolet radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H584300\">",
"      - Extent of sun exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H584307\">",
"      - History of sunburn",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H584314\">",
"      - Impact of sun protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H624970\">",
"      Phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H422395\">",
"      Gender, age, and geographic location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H421852\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H584493\">",
"      - Genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H624962\">",
"      - Human papillomavirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H421788\">",
"      - Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17075261\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17075268\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H422059\">",
"      Progression to skin cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H422105\">",
"      Spontaneous resolution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H625576\">",
"      Risk for skin cancer in other sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17075275\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H625191\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1503601\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H625412\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H625419\">",
"      - Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H625426\">",
"      Dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34235306\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13712\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13712|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/27/23988\" title=\"picture 1A\">",
"      Actinic keratosis - dorsal hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/19/26932\" title=\"picture 1B\">",
"      Actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/20/16709\" title=\"picture 2A\">",
"      Hypertrophic actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/61/37843\" title=\"picture 2B\">",
"      Multiple actinic keratoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/26/18852\" title=\"picture 3\">",
"      Cutaneous horn on the cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/49/43794\" title=\"picture 4A\">",
"      Actinic cheilitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/35/18995\" title=\"picture 4B\">",
"      Actinic cheilitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/24/2434\" title=\"picture 4C\">",
"      Actinic cheilitis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/26/40358\" title=\"picture 5\">",
"      Cutaneous squamous cell carcinoma - dorsal hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/56/11143\" title=\"picture 6\">",
"      Benign lichenoid keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/50/17188\" title=\"picture 7\">",
"      Superficial basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/18/12582\" title=\"picture 8\">",
"      Inflamed seborrheic keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/36/44610\" title=\"picture 9A\">",
"      Disseminated superficial actinic porokeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/51/10038\" title=\"picture 9B\">",
"      Disseminated superficial actinic porokeratosis close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/28/42433\" title=\"picture 10A\">",
"      Guttate psoriasis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/14/3301\" title=\"picture 10B\">",
"      Seborrheic dermatitis ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/58/34721\" title=\"picture 10C\">",
"      Seborrheic dermatitis face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/63/25587\" title=\"picture 11\">",
"      Cutaneous squamous cell carcinoma - cutaneous horn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/17/9488\" title=\"picture 12\">",
"      Common warts PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/40/16015\" title=\"picture 13\">",
"      Seborrheic keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/3/23606\" title=\"picture 14\">",
"      Seborrehic keratosis - pigmented",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/10/6306\" title=\"picture 15\">",
"      Solar lentigo hand 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/50/18211\" title=\"picture 16\">",
"      Lentigo maligna melanoma 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/6/40036\" title=\"picture 17A\">",
"      Actinic keratosis histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/44/11974\" title=\"picture 17B\">",
"      Actinic keratosis histopathology 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35493?source=related_link\">",
"      Bloom syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/8/19586?source=related_link\">",
"      Patient information: Actinic keratosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=related_link\">",
"      Sunburn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30968?source=related_link\">",
"      Treatment of actinic keratosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_49_18201="Restoration of sinus rhythm in atrial flutter";
var content_f17_49_18201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Restoration of sinus rhythm in atrial flutter",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/49/18201/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/49/18201/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/49/18201/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/49/18201/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/49/18201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/49/18201/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/49/18201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter is a relatively common arrhythmia that is characterized by rapid, regular atrial depolarizations at a characteristic rate of approximately 300",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    It can be deleterious by impairing the cardiac output, increasing myocardial oxygen demand, and by promoting atrial thrombus formation that can lead to systemic embolization. Restoration of sinus rhythm can improve the clinical status of many patients, particularly those in whom a rapid ventricular rate has induced hypotension and lightheadedness or has exacerbated underlying heart failure (HF) or angina pectoris.",
"   </p>",
"   <p>",
"    Atrial flutter is often an electrically unstable rhythm, meaning that it frequently degenerates into the less organized arrhythmia atrial fibrillation (AF) or reverts to sinus rhythm within hours or days. Spontaneous reversion to a sinus mechanism often occurs after predisposing problems are improved, such as decompensated HF and the sequelae of cardiac surgery. Chronic atrial flutter is uncommon and is frequently associated with biventricular and biatrial enlargement, prior cardiac surgery or atrial fibrillation ablation, or congenital heart disease.",
"   </p>",
"   <p>",
"    Most patients with chronic atrial flutter can be cardioverted successfully to normal sinus rhythm, but the maintenance of sinus rhythm is often problematic, as it is in AF. Restoration and maintenance of sinus rhythm is more likely if the arrhythmia is of recent onset, the left atrium (LA) shows little or no enlargement, and ventricular dysfunction is not prominent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the indications and therapeutic options for the restoration of sinus rhythm in atrial flutter will be reviewed here. Causes of atrial flutter, rate control therapy, the maintenance of sinus rhythm after cardioversion, and the role of anticoagulation in atrial flutter are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=see_link\">",
"     \"Atrial flutter: Epidemiology, classification, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=see_link\">",
"     \"Control of ventricular rate in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=see_link\">",
"     \"Embolic risk and the role of anticoagulation in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR RESTORATION OF SINUS RHYTHM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter is an electrically unstable rhythm. As a result, many patients will either revert spontaneously to sinus rhythm within days to weeks or degenerate to AF.",
"   </p>",
"   <p>",
"    Thus, watchful waiting may be all that is required in a patient with stable hemodynamics. However, the ventricular response in atrial flutter is often rapid and difficult to control with rate control therapy, and it may not be possible to wait for spontaneous reversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=see_link\">",
"     \"Control of ventricular rate in atrial flutter\"",
"    </a>",
"    .) Factors that predict spontaneous reversion to sinus rhythm or a successful cardioversion are similar to those for AF, and include a left atrial size less than 4.5 to 5 cm, atrial flutter of recent onset, little or no heart failure, and no underlying reversible cause such as hyperthyroidism, myocardial infarction, or pulmonary embolism.",
"   </p>",
"   <p>",
"    Among those who have chronic atrial flutter, restoration of sinus rhythm is usually favored. This is in contrast to AF, in which tolerance of permanent AF with a rate control strategy is often preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reasons for the more aggressive approach in atrial flutter include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definitive therapy for the permanent elimination of the most common form of atrial flutter is more effective, with fewer risks, than it is for AF. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Ablation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Rate control is often more difficult in atrial flutter than it is in AF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=see_link\">",
"       \"Control of ventricular rate in atrial flutter\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The standard indications for cardioversion in patients with AF can be applied to patients with atrial flutter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications for cardioversion include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial flutter with a rapid ventricular response, when signs or symptoms of hemodynamic instability (eg, ischemia, HF, hypotension) are present and the heart rate cannot be promptly controlled with pharmacologic therapy.",
"     </li>",
"     <li>",
"      Atrial flutter with preexcitation and a rapid ventricular rate.",
"     </li>",
"     <li>",
"      Patient preference, which may be most important in patients with often vague symptoms that are attributed to atrial flutter (eg, dyspnea, fatigue, palpitations).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28313511\">",
"    <span class=\"h2\">",
"     Reasons to not cardiovert",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumstances in which it is reasonable to avoid cardioversion attempts in patients with new onset atrial flutter include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are",
"      <strong>",
"       completely asymptomatic",
"      </strong>",
"      , particularly those who are elderly (&gt;80 years) with multiple comorbidities or poor overall prognosis, where the risks of undergoing cardioversion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pharmacologic rhythm control may outweigh the benefits of restoring sinus rhythm.",
"     </li>",
"     <li>",
"      Patients who have a bleeding risk and cannot be anticoagulated during the peri-cardioversion and post-cardioversion periods.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ELECTRICAL CARDIOVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical cardioversion, also called direct current (DC) cardioversion, has become a routine procedure in the management of patients with cardiac arrhythmias. It is expected that normal sinus rhythm will resume once the atrial flutter terminates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With appropriate patient selection and technique, DC cardioversion is rapid, effective, and safe. As a result, it is the preferred means for restoring sinus rhythm in patients with a variety of arrhythmias, including atrial flutter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2012 American College of Chest Physicians guideline on antithrombotic therapy in atrial fibrillation and the 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society focused update of prior guidelines on atrial fibrillation recommend that consideration be given to managing anticoagulation during cardioversion of atrial flutter in a manner similar to that for AF [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical cardioversion should be performed by physicians experienced in the procedure. The patient should be fasting, serum electrolytes should be normal, and drug levels, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , should be within the therapeutic range. Cardioversion techniques are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to basic techniques, the performing physician should consider the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The procedure room should be equipped for pulmonary resuscitation.",
"     </li>",
"     <li>",
"      Because deep sedation with amnesia is required, the physician should be experienced with moderate or deep sedation techniques, including drug reversal if necessary and emergent airway management. Some physicians prefer the presence of an anesthesiologist to address these concerns.",
"     </li>",
"     <li>",
"      Because atrial flutter may be part of a bradycardia-tachycardia syndrome, the physician should be prepared to manage a bradyarrhythmia following termination of atrial flutter (eg, with transcutaneous pacing, temporary transvenous pacing, or drug therapy). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link&amp;anchor=H5#H5\">",
"       \"Manifestations and causes of the sick sinus syndrome\", section on 'Tachycardia-bradycardia syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Energy levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with type I atrial flutter can be cardioverted with 50 to 100 joules, particularly with biphasic defibrillators [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In a review including 985 cardioversions in 840 patients with atrial flutter, the median energy level for successful cardioversion was 50 joules with a biphasic defibrillatory and 200 joules with a monophasic defibrillator [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We usually begin at 100 joules for type I atrial flutter and 200 joules for type II atrial flutter, which may be more resistant. Starting at lower energy levels may be effective, particularly with biphasic defibrillators, but has the potential adverse effect of necessitating additional shocks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link&amp;anchor=H14#H14\">",
"     \"Cardioversion for specific arrhythmias\", section on 'Atrial flutter'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Digitalis toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digitalis toxicity sensitizes the myocardium to the effects of electricity. Cardioversion or defibrillation in the setting of clinical digitalis toxicity is contraindicated due to the possible induction of malignant ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/1,7-9\">",
"     1,7-9",
"    </a>",
"    ]. If possible, cardioversion should be deferred until digitalis levels have returned to a normal range and clinical toxicity has resolved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If urgent restoration of sinus rhythm is necessary in the setting of digitalis toxicity, rapid atrial pacing is probably the safest method. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Atrial pacing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28313518\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC ENHANCEMENT OF DIRECT CURRENT CARDIOVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the success of DC cardioversion is high for atrial flutter, antiarrhythmic drugs may be initiated prior to electrical cardioversion to increase the likelihood of successful cardioversion and long-term maintenance of sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link&amp;anchor=H8701669#H8701669\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Pretreatment with antiarrhythmic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to pretreat is often made by a physician experienced with the care of patients with one or more risk factors for cardioversion failure. (See",
"    <a class=\"local\" href=\"#H28313511\">",
"     'Reasons to not cardiovert'",
"    </a>",
"    above.) In addition, the antiarrhythmic drug may restore sinus rhythm prior to DC cardioversion in some cases. Another reason to consider starting an antiarrhythmic drug before cardioversion is that it might help prevent recurrent episodes of atrial flutter very soon after cardioversion.",
"   </p>",
"   <p>",
"    A third reason to consider pretreatment with antiarrhythmic drugs prior to DC cardioversion is that for patients in whom long term antiarrhythmic therapy will be used, early initiation (prior to DC cardioversion) may allow for an evaluation of tolerability of one or more drugs. For those patients in whom a decision has been made to attempt the long term maintenance of sinus rhythm with antiarrhythmic drug therapy, it is reasonable to preferentially select a drug for cardioversion that can also be used for long term maintenance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC CARDIOVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of antiarrhythmic drugs may be used to terminate atrial flutter and restore sinus rhythm. However, antiarrhythmic drugs are less effective than DC cardioversion and carry some degree of proarrhythmic risk. Thus, pharmacologic cardioversion is generally reserved for selected clinical scenarios. The most common reason for selecting pharmacologic cardioversion is that moderate or deep sedation is either unavailable or is expected to be poorly tolerated (eg, due to hypotension).",
"   </p>",
"   <p>",
"    Most of the available data on the efficacy of antiarrhythmic drugs for the restoration of sinus rhythm are from patients with AF. The drugs that are effective in converting AF to sinus rhythm may also be effective in converting atrial flutter. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link&amp;anchor=H8701755#H8701755\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Antiarrhythmic drugs used in cardioversion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the extrapolation of data from patients with AF to those with atrial flutter, there is a modest amount of direct evidence regarding the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    for the conversion of atrial flutter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ibutilide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    , approved by the Food and Drug Administration only for intravenous use, converts atrial flutter to sinus rhythm in approximately 60 percent of patients (compared to a 0 to 2 percent response to placebo) with a mean time to conversion of 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Ibutilide is more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    for reversion of atrial flutter (64 to 76 versus 0 to 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and is also more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    (70 versus 19 percent) (",
"    <a class=\"graphic graphic_figure graphicRef51703 \" href=\"UTD.htm?23/17/23837\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/16\">",
"     16",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (87 versus 29 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40118?source=see_link\">",
"     \"Therapeutic use of ibutilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like other Class III antiarrhythmic drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    prolongs the atrial flutter cycle length due to prolongation of atrial refractoriness; there is also an increase in atrial cycle length variability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. These changes can lead to abolition of the fully excitable gap in the atrial flutter reentrant circuit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     QT prolongation and torsades de pointes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious concern with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    is QT interval prolongation that can lead to torsades de pointes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The potential for torsades de pointes is increased in patients with severe heart failure or those who are being treated with another drug that prolongs the QT interval. On the other hand, the risk of proarrhythmia does not appear to be increased when ibutilide is given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the risk of torsades de pointes, patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    should be observed with continuous ECG monitoring for at least four hours after the infusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40118?source=see_link&amp;anchor=H7#H7\">",
"     \"Therapeutic use of ibutilide\", section on 'Proarrhythmia'",
"    </a>",
"    .) The addition of intravenous magnesium, in doses of 4 to 10 grams, can enhance the cardioverting effect of ibutilide and may reduce the risk of torsades de pointes as well [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dofetilide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    is effective for conversion of atrial flutter and the conversion rate appears to be higher than in AF. As an example, the SAFIRE-D study randomly assigned 325 patients with AF (n = 277) or atrial flutter (n = 48) to 125, 250, and 500 &micro;g of dofetilide twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/24\">",
"     24",
"    </a>",
"    ]. At a dose of 500 &micro;g, the conversion rates for AF and atrial flutter were 22 and 67 percent, respectively, compared to 1.2 percent for placebo. Conversion to sinus rhythm occurred in 70 percent within 24 hours, while 91 percent converted within 36 hours.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , which is not available in the United States, also appears to be effective for conversion of atrial flutter. In one study of 16 patients, 54 percent reverted to sinus rhythm after dofetilide administration while in another series of 17 patients the rate of reversion was 64 percent, compared with 0 percent for placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    is more effective than intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . In a randomized trial that included 31 patients with atrial flutter, the reversion rate with dofetilide was 75 percent versus 0 and 10 percent for amiodarone and placebo, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prolongation of the QT interval can occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    and has led to torsades de pointes in 3 to 8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Class I antiarrhythmic drugs and accelerated ventricular rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The class IC agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    are among the options suggested for pharmacologic conversion of AF and may be considered for the conversion of atrial flutter, though are less efficacious than other agents. Class IA drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ) are not recommended for conversion of AF or atrial flutter, although they are sometimes used both for conversion of atrial arrhythmias and for the maintenance of sinus rhythm.",
"   </p>",
"   <p>",
"    Compared to other antiarrhythmic drugs, class I (both IA and IC) drugs carry an additional risk in the treatment of atrial arrhythmias.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The class IA antiarrhythmic drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      ) both slow the atrial flutter rate and have a significant vagolytic effect which increases AV nodal conduction. These combined actions can result in 1:1 conduction at very rapid ventricular rates (",
"      <a class=\"graphic graphic_waveform graphicRef55441 \" href=\"UTD.htm?14/20/14662\">",
"       waveform 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The class IC agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ) do not accelerate AV conduction, but can slow the atrial flutter rate, often to a greater extent than the class IA drugs. Slowing of the atrial flutter rate alone (eg, to 200 or 250",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      can lead to 1:1 conduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To prevent this adverse effect, class IA and IC drugs should be administered in conjunction with an AV nodal blocking agent, such as a beta blocker or a nondihydropyridine calcium channel blocker (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ). Because patients with AF may develop atrial flutter when treated with an antiarrhythmic drug, the requirement for the simultaneous treatment with AV nodal blocking drugs applies to patients with AF, atrial flutter, or both arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rate control drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    , nondihydropyridine calcium channel blockers, and beta blockers can all be effective in the control of the ventricular rate during atrial flutter. Although the hemodynamic improvement associated with a normalized ventricular rate may indirectly facilitate reversion to sinus rhythm, these drugs should only be considered for the purpose of rate control, not for restoring sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=see_link\">",
"     \"Control of ventricular rate in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      &mdash; Digoxin&nbsp;",
"      <strong>",
"       rarely",
"      </strong>",
"      , if ever, converts atrial flutter to a normal sinus rhythm. In our experience, high doses of digoxin are required to produce effective rate control. Digoxin is rarely used as monotherapy in atrial flutter and it is only infrequently used as part of combination therapy, unless the presence of HF justifies its continued use.",
"     </li>",
"     <li>",
"      Nondihydropyridine calcium channel blockers &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      and, to a lesser extent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , have been evaluated in the management of atrial flutter. These drugs can slow the ventricular response and, in this setting, some patients revert to sinus rhythm [",
"      <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/28-30\">",
"       28-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta blockers &mdash; There are few data about the effect of beta blockers in the reversion of atrial flutter. However, similar to calcium channel blockers, beta blockers can be effective for slowing the ventricular rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28313610\">",
"    <span class=\"h2\">",
"     Vernakalant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous vernakalant is approved by the European commission for the rapid conversion of recent-onset atrial fibrillation (&le;7 days duration for patients not undergoing surgery, and &le;3 days duration for postcardiac surgery patients) to SR. This drug is not available in the United States.",
"   </p>",
"   <p>",
"    Vernakalant blocks sodium and potassium currents, including the atrial-selective currents IKur&nbsp;and IK,Ach [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/31\">",
"     31",
"    </a>",
"    ]. Vernakalant significantly prolongs the atrial refractory period with minimal effects on ventricular refractoriness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link&amp;anchor=H10#H10\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\", section on 'Class III'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of vernakalant for the restoration of SR from atrial flutter has been evaluated in the ACT III trial, which included 23 patients with atrial flutter, 14 of whom received vernakalant [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/32\">",
"     32",
"    </a>",
"    ]. Vernakalant was given as a 10-minute intravenous infusion at a dose of 3 mg per kg followed by a second 10-minute infusion at a dose of 2 mg per kg 15 minutes later if atrial flutter had not been terminated. Only 1 of 14 converted to normal sinus rhythm with vernakalant versus 0 of 9 receiving placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER METHODS FOR RESTORING SINUS RHYTHM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical and pharmacologic cardioversion are the most common methods for restoring sinus rhythm. In some circumstances, sinus rhythm can also be restored as part of an ablation procedure or with rapid atrial pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency ablation (RFA) is increasingly used to interrupt the reentrant circuit supporting atrial flutter in order to permanently restore normal sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/33\">",
"     33",
"    </a>",
"    ]. It is becoming more accepted that RFA, rather than pharmacologic therapy, is the",
"    <strong>",
"     first-line",
"    </strong>",
"    therapy for the long-term maintenance of sinus rhythm in patients with type I atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RFA is usually done electively for the purpose of preventing the recurrence of atrial flutter, rather than for the acute restoration of sinus rhythm. However, RFA can be performed during atrial flutter and, in this setting, sinus rhythm is restored during the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Atrial pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I atrial flutter is a reentrant arrhythmia, and it is therefore possible to entrain and terminate the arrhythmia with rapid pacing with a success rate of 55 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/35\">",
"     35",
"    </a>",
"    ]. Due to the availability of alternative therapies, this is not a common clinical practice, but can be useful in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In type I atrial flutter, if the atrium is paced approximately 10 percent faster than the atrial flutter rate for 15 to 30 seconds, the rate of the tachycardia increases to match that of the faster pacing rate; that is, it is entrained [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the pacing rate is then slowed or pacing discontinued, one of several results may ensue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The original rate of the atrial flutter may return.",
"     </li>",
"     <li>",
"      The atrial flutter may cease with restoration of normal sinus rhythm (",
"      <a class=\"graphic graphic_waveform graphicRef56947 \" href=\"UTD.htm?42/11/43191\">",
"       waveform 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The patient may convert to AF.",
"     </li>",
"     <li>",
"      Infrequently, the atrial flutter rate can be accelerated [",
"      <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Atrial pacing and entrainment can be useful in several settings, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/35-38,40,41\">",
"     35-38,40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After cardiac surgery, since atrial pacing wires are often left in place during the early postoperative period.",
"     </li>",
"     <li>",
"      In patients with a pacemaker or implantable cardioverter-defibrillator where rapid pacing may be available through the device.",
"     </li>",
"     <li>",
"      In patients who have recurrent atrial flutter due to an acute stress such as a myocardial infarction or respiratory failure; this represents a setting in which one would like to avoid repeated DC shocks.",
"     </li>",
"     <li>",
"      In patients who have digitalis toxicity, a condition in which DC cardioversion may be particularly dangerous.",
"     </li>",
"     <li>",
"      In patients in whom anesthesia is a risk [",
"      <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/5,9,36-38\">",
"       5,9,36-38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The success rate of rapid atrial pacing may be increased by the concurrent intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/20,42,43\">",
"     20,42,43",
"    </a>",
"    ]. Ibutilide may promote pace termination by the formation of functional blocks that lead to new, unstable, and short-lived reentry [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transesophageal pacing is another modality that has been used to convert atrial flutter in a small number of patients. It results in the immediate restoration of sinus rhythm in 15 to 50 percent of patients, while up to an additional 40 percent convert to sinus rhythm after a transient period of atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/44\">",
"     44",
"    </a>",
"    ]. The efficacy of this technique for the prompt restoration of sinus rhythm can be increased with the concomitant use of oral or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An implantable permanent atrial pacemaker has been used for refractory atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/47\">",
"     47",
"    </a>",
"    ] and in patients with atrial fibrillation who also have organized atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/48\">",
"     48",
"    </a>",
"    ]. The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    device guidelines state that permanent atrial pacemaker (pacing) with anti-tachycardia pacing therapies is reasonable for symptomatic, recurrent supraventricular tachycardias, including atrial flutter, that can be reproducibly terminated with atrial pacing when pharmacologic therapy or catheter ablation have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/49\">",
"     49",
"    </a>",
"    ]. This recommendation was not changed in the 2012",
"    <span class=\"nowrap\">",
"     ACCF/AHA/HRS",
"    </span>",
"    focused update [",
"    <a class=\"abstract\" href=\"UTD.htm?17/49/18201/abstract/50\">",
"     50",
"    </a>",
"    ]. It is used rarely, however, given the success of other treatments, particularly catheter ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=see_link\">",
"       \"Patient information: Atrial flutter (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to the restoration of sinus rhythm in patients with atrial flutter. They are similar to those for patients with AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Indications for cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent or elective cardioversion of atrial flutter is indicated in several settings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with atrial flutter and a rapid ventricular response in whom pharmacologic rate control is either ineffective, poorly tolerated, or expected to be poorly tolerated, who also have evidence of hemodynamic instability including myocardial ischemia, hypotension, angina, or heart failure, we recommend urgent cardioversion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for restoration of sinus rhythm'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with atrial flutter and hemodynamic compromise, but with a controlled ventricular rate (eg, &le;100",
"    <span class=\"nowrap\">",
"     beats/min),",
"    </span>",
"    explanations for hemodynamic instability other than the atrial flutter should be sought.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with atrial flutter and preexcitation with a rapid ventricular rate, we recommend urgent cardioversion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for restoration of sinus rhythm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with persistent symptoms (eg, palpitations, dyspnea, or fatigue) that are attributed to atrial flutter and do not resolve despite attempts to control the ventricular rate, we suggest cardioversion, which can be done electively (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for restoration of sinus rhythm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For any patient with type I (typical) atrial flutter who would be a candidate for radiofrequency ablation (RFA) for the prevention of recurrent atrial flutter, we suggest restoration of sinus rhythm (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Ablation'",
"      </a>",
"      above.) This suggestion applies to the majority of patients with type I atrial flutter, since RFA is suggested for most patients with this arrhythmia. In such patients, cardioversion may be performed prior to the procedure or sinus rhythm may be restored during the procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"       \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"       \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Method of cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to greater efficacy and lower risks, we generally prefer electrical to pharmacologic cardioversion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who require urgent cardioversion, we recommend electrical as opposed to pharmacologic cardioversion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Electrical Cardioversion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require elective cardioversion who can tolerate moderate or deep sedation, we recommend electrical cardioversion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Electrical Cardioversion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with digitalis toxicity, we recommend that electrical cardioversion",
"      <strong>",
"       not",
"      </strong>",
"      be performed (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Digitalis toxicity'",
"      </a>",
"      above.) In such patients, options include deferring cardioversion until digitalis toxicity resolves or rapid atrial pacing. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Atrial pacing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who cannot tolerate moderate or deep sedation or if moderate or deep sedation is not available, we suggest pharmacologic cardioversion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pharmacologic cardioversion'",
"      </a>",
"      above.) Available data do not support the recommendation of a specific antiarrhythmic for this purpose, and options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"       ibutilide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      . Among these antiarrhythmic drug options, the only ones that are available in an intravenous form in the United States are ibutilide and amiodarone. Based upon evidence of its superior efficacy, we prefer ibutilide in situations where we desire acute pharmacologic cardioversion of atrial flutter. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ibutilide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with atrial pacing wires in place (either as part of a permanent pacemaker, implantable-cardioverter defibrillator, or temporary pacing wires after cardiac surgery), we suggest rapid atrial pacing rather than electrical cardioversion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Atrial pacing'",
"      </a>",
"      above.) However, because rapid atrial pacing can cause atrial flutter to degenerate into AF, the physician should be prepared for the management of AF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding the need for anticoagulation prior to and after cardioversion are made according to guidelines for patients with AF. Important considerations include the duration of atrial flutter, the urgency of the need for cardioversion, and the patient's thromboembolic risk profile. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to chronic anticoagulation in patients with atrial flutter are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=see_link\">",
"     \"Embolic risk and the role of anticoagulation in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Maintenance of sinus rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options and decisions regarding the maintenance of sinus rhythm in patients with atrial flutter are discussed separately. For the majority of patients with type I atrial flutter, RFA is considered as a first-line therapy to prevent recurrence of atrial flutter. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Ablation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/1\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/2\">",
"      You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e531S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/3\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/4\">",
"      Niebauer MJ, Brewer JE, Chung MK, Tchou PJ. Comparison of the rectilinear biphasic waveform with the monophasic damped sine waveform for external cardioversion of atrial fibrillation and flutter. Am J Cardiol 2004; 93:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/5\">",
"      Resnekov L. Cardiac arrhythmias. 6. Present status of electroversion in the management of cardiac dysrhythmias. Circulation 1973; 47:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/6\">",
"      Gallagher MM, Guo XH, Poloniecki JD, et al. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol 2001; 38:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/7\">",
"      Kleiger R, Lown B. Cardioversion and digitalis. II. Clinical studies. Circulation 1966; 33:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/8\">",
"      Ditchey RV, Karliner JS. Safety of electrical cardioversion in patients without digitalis toxicity. Ann Intern Med 1981; 95:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/9\">",
"      Mann DL, Maisel AS, Atwood JE, et al. Absence of cardioversion-induced ventricular arrhythmias in patients with therapeutic digoxin levels. J Am Coll Cardiol 1985; 5:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/10\">",
"      Naccarelli GV, Dell'Orfano JT, Wolbrette DL, et al. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol 2000; 85:36D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/11\">",
"      Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/12\">",
"      Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996; 28:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/13\">",
"      Abi-Mansour P, Carberry PA, McCowan RJ, et al. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am Heart J 1998; 136:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/14\">",
"      Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation 1997; 96:4298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/15\">",
"      Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998; 31:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/16\">",
"      Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998; 79:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/17\">",
"      Kafkas NV, Patsilinakos SP, Mertzanos GA, et al. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. Int J Cardiol 2007; 118:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/18\">",
"      Tai CT, Chen SA, Feng AN, et al. Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination. Circulation 1998; 97:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/19\">",
"      Guo GB, Ellenbogen KA, Wood MA, Stambler BS. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol 1996; 27:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/20\">",
"      Cheng J, Glatter K, Yang Y, et al. Electrophysiological response of the right atrium to ibutilide during typical atrial flutter. Circulation 2002; 106:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/21\">",
"      Glatter K, Yang Y, Chatterjee K, et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 2001; 103:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/22\">",
"      Patsilinakos S, Christou A, Kafkas N, et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol 2010; 106:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/23\">",
"      Tercius AJ, Kluger J, Coleman CI, White CM. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter. Pacing Clin Electrophysiol 2007; 30:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/24\">",
"      Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/25\">",
"      Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997; 29:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/26\">",
"      N&oslash;rgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J 1999; 137:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/27\">",
"      Bianconi L, Castro A, Dinelli M, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J 2000; 21:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/28\">",
"      Schamroth L, Krikler DM, Garrett C. Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J 1972; 1:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/29\">",
"      Hagemeijer F. Verapamil in the management of supraventricular tachyarrhythmias occurring after a recent myocardial infarction. Circulation 1978; 57:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/30\">",
"      Wolfson S, Herman MV, Sullivan JM, Gorlin R. Conversion of atrial fibrillation and flutter by propranolol. Br Heart J 1967; 29:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/31\">",
"      Naccarelli GV, Wolbrette DL, Samii S, et al. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin Investig Drugs 2008; 17:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/32\">",
"      Pratt CM, Roy D, Torp-Pedersen C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 2010; 106:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/33\">",
"      Saoudi N, Atallah G, Kirkorian G, Touboul P. Catheter ablation of the atrial myocardium in human type I atrial flutter. Circulation 1990; 81:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/34\">",
"      Da Costa A, Th&eacute;venin J, Roche F, et al. Results from the Loire-Ard&egrave;che-Dr&ocirc;me-Is&egrave;re-Puy-de-D&ocirc;me (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. Circulation 2006; 114:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/35\">",
"      Das G, Anand KM, Ankineedu K, et al. Atrial pacing for cardioversion of atrial flutter in digitalized patients. Am J Cardiol 1978; 41:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/36\">",
"      Waldo AL, MacLean WA, Karp RB, et al. Entrainment and interruption of atrial flutter with atrial pacing: studies in man following open heart surgery. Circulation 1977; 56:737.",
"     </a>",
"    </li>",
"    <li>",
"     Waldo AL, Carlson MD, Biblo LA, Henthorn RW. The role of transient entrainment in atrial flutter. In: Atrial Arrhythmias: Current Concepts and Management, Tourboul P, Waldo AL (Eds), Mosby Year Book, St Louis 1990. p.210.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/38\">",
"      Greenberg ML, Kelly TA, Lerman BB, DiMarco JP. Atrial pacing for conversion of atrial flutter. Am J Cardiol 1986; 58:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/39\">",
"      Cheng J, Scheinman MM. Acceleration of typical atrial flutter due to double-wave reentry induced by programmed electrical stimulation. Circulation 1998; 97:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/40\">",
"      Peters RW, Shorofsky SR, Pelini M, et al. Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. Am Heart J 1999; 137:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/41\">",
"      Orlando J, Cassidy J, Aronow WS. High reversion of atrial flutter to sinus rhythm after atrial pacing in patients with pulmonary disease. Chest 1977; 71:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/42\">",
"      Olshansky B, Okumura K, Hess PG, et al. Use of procainamide with rapid atrial pacing for successful conversion of atrial flutter to sinus rhythm. J Am Coll Cardiol 1988; 11:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/43\">",
"      Stambler BS, Wood MA, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996; 77:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/44\">",
"      Crawford W, Plumb VJ, Epstein AE, Kay GN. Prospective evaluation of transesophageal pacing for the interruption of atrial flutter. Am J Med 1989; 86:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/45\">",
"      Doni F, Della Bella P, Kheir A, et al. Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. Am J Cardiol 1995; 76:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/46\">",
"      D'Este D, Bertaglia E, Mantovan R, et al. Efficacy of intravenous propafenone in termination of atrial flutter by overdrive transesophageal pacing previously ineffective. Am J Cardiol 1997; 79:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/47\">",
"      Barold SS, Wyndham CR, Kappenberger LL, et al. Implanted atrial pacemakers for paroxysmal atrial flutter. Long-term efficacy. Ann Intern Med 1987; 107:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/48\">",
"      Israel CW, Ehrlich JR, Gr&ouml;nefeld G, et al. Prevalence, characteristics and clinical implications of regular atrial tachyarrhythmias in patients with atrial fibrillation: insights from a study using a new implantable device. J Am Coll Cardiol 2001; 38:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/49\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/49/18201/abstract/50\">",
"      Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2012; 9:1737.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1069 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18201=[""].join("\n");
var outline_f17_49_18201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR RESTORATION OF SINUS RHYTHM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28313511\">",
"      Reasons to not cardiovert",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ELECTRICAL CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Energy levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Digitalis toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28313518\">",
"      PHARMACOLOGIC ENHANCEMENT OF DIRECT CURRENT CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PHARMACOLOGIC CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ibutilide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - QT prolongation and torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dofetilide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Class I antiarrhythmic drugs and accelerated ventricular rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rate control drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28313610\">",
"      Vernakalant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER METHODS FOR RESTORING SINUS RHYTHM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Atrial pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Indications for cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Method of cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Maintenance of sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1069\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1069|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/17/23837\" title=\"figure 1\">",
"      Ibutilide sotalol AF flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1069|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?14/20/14662\" title=\"waveform 1\">",
"      Type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/11/43191\" title=\"waveform 2\">",
"      Atrial flutter Entrainment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36228?source=related_link\">",
"      Atrial flutter: Epidemiology, classification, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18328?source=related_link\">",
"      Control of ventricular rate in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=related_link\">",
"      Embolic risk and the role of anticoagulation in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=related_link\">",
"      Maintenance of sinus rhythm after cardioversion in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=related_link\">",
"      Patient information: Atrial flutter (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40118?source=related_link\">",
"      Therapeutic use of ibutilide",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_49_18202="Aspergillus bronchopneumonia histopathology";
var content_f17_49_18202=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Aspergillus bronchopneumonia histopathology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Magnified view of a slice of lower lobe shows multiple foci of necrosis, some clearly centered on airways (arrows) as indicated by their intimate association with pulmonary arteries. The lung parenchyma adjacent to the necrotic regions is hemorrhagic.",
"    <br>",
"     (Panel B) Photomicrograph shows small colonies of Aspergillus (arrow) within a bronchial lumen (L) and wall (W). Extension of fungus can also be seen into the adjacent pulmonary artery, which is partly occluded by thrombus (T). An infiltrate of neutrophils (N) is evident in the adjacent lung.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: M&uuml;ller NL, Fraser RS, Lee KS, Johkoh T. Pulmonary infections. In: Diseases of the Lung, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"     </div>",
"     <div class=\"contractual\">",
"      <br/>",
"      <a href=\"file://www.lww.com\">",
"       file://www.lww.com",
"      </a>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18202=[""].join("\n");
var outline_f17_49_18202=null;
var title_f17_49_18203="Strategies rx depression IFN";
var content_f17_49_18203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Algorithm for pretreatment vs. symptomatic treatment of neuropsychiatric side effects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Prophylaxis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mild or greater depressive/anxiety symptoms just prior to IFN-alfa initiation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Receiving ongoing treatment for a psychiatric condition",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Developed psychiatric symptoms during prior IFN-alfa treatment",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Patient requests pretreatment",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Symptomatic Rx",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          No depressive/anxiety symptoms prior to IFN-alfa treatment",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          No past psychiatric history",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tolerated prior IFN-alfa treatment without psychiatric side effects",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Raison, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18203=[""].join("\n");
var outline_f17_49_18203=null;
var title_f17_49_18204="Radiological evaluation of precocious puberty";
var content_f17_49_18204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Radiological evaluation of precocious puberty",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bone age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Gonadotropin dependent precocious puberty (GDPP)",
"       </td>",
"       <td class=\"centered\" rowspan=\"2\">",
"        &uarr; &uarr;",
"       </td>",
"       <td>",
"        Cranial MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonadal ultrasound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primary hypothyroidism",
"       </td>",
"       <td class=\"centered\">",
"        &darr;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Gonadotropin independent precocious puberty (GIPP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Gonadotropin-secreting tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"2\">",
"        Germ-cell tumor (hCG)",
"       </td>",
"       <td class=\"centered\" rowspan=\"2\">",
"        &uarr; &uarr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        Tumor search: brain, liver, testes, peritoneum, mediastinum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Pituitary MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Gonadotropin-secreting adenoma",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gonadal autonomy",
"       </td>",
"       <td class=\"centered\">",
"        &uarr; &uarr;",
"       </td>",
"       <td>",
"        Gonadal ultrasound; skeletal survey, bone scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adrenal pathology",
"       </td>",
"       <td class=\"centered\">",
"        &uarr; &uarr;",
"       </td>",
"       <td>",
"        Adrenal CT if tumor suspected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Incomplete precocious puberty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Premature thelarche",
"       </td>",
"       <td class=\"centered\">",
"        slightly &uarr;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Premature adrenarche",
"       </td>",
"       <td class=\"centered\">",
"        &uarr;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     hCG: human chorionic gonadotropin; MRI: magnetic resonance imaging; CT: computerized tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18204=[""].join("\n");
var outline_f17_49_18204=null;
var title_f17_49_18205="Segmental volume plethysmography";
var content_f17_49_18205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Segmental volume plethysmography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 266px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Variations in the contours of the pulse volume recording with segmental volume plethysmography reflect the severity of peripheral vascular disease. Mild disease is characterized by the absence of a dicrotic notch. With progressive obstruction, the upstroke and downstroke become equal, and with severe disease, the amplitude of the waveform is blunted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18205=[""].join("\n");
var outline_f17_49_18205=null;
var title_f17_49_18206="Causes of see saw nystagmus";
var content_f17_49_18206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Causes of see-saw nystagmus in 42 patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 286px; background-image: url(data:image/gif;base64,R0lGODlhqQEeAfcAAP///wAzmSBzOaekqf8AAGYzZgAAAP+ZM4CAgMDAwEBAQKCgoBAQEPDw8ODg4NDQ0GBgYFBQUCAgIDAwMHBwcLCwsAADCZCQkAAvj+8AAAAZTAAJHL8AAB5rNQApfAAGEwAfXwAmci8AAJyZngAMJg8AAH17fgIHAz49Pw8JAykpKgYVCggcDgoKCu+PLz8AAFksWTMZM38AAD8fPwAshc8AABpdLhQUFVNSVCYTJl8vXwwGDAATOQYDBt+FLBkMGZKPk2hmaR8TBp8AAF8AAB8eH185EwwrFQQOBxRHIwAcVoeFiRMJE0wmTDQzNB8AABhWKr9yJp9fHwAPLywWLE8AAB8PH0lHSXJwdDkcOT8mDH9MGV1cX48AABxkMQAWQhA5HB5vP0YjRm8AAN8AAI9WHFIpUhpjQS8cCQojEQINFg4yGBJAIM98KW9CFhZPJ08vD68AAK9pIxoZGgAjaXp6egYfJxRRQMrKyjQ0NQw3O2pqagYYFAwuHgYbHQQRENLX1GVkZSoqKhZbTRxrRQIKDbS0tRA/LwYlOrq6utra2ggjIfr6+hRUSaqqqkpKShxnOxZVOhhfRwYiMBRONpSelxRLLRhcPaSupxpgNzo6OxhZNA44LBBJTBJNRg5FUhJKPAQUGgwxKJqamiInIwotLlRUVQYoRAIQIBpnS8TExQITKQw7RQQXIwIXMw5CSAoqJBBDOQw+ThRXU/L38wowOFFXU1paWgw0MggvRwgmKg47NQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACpAR4BAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDiBOvfJCgceMHIxEogOxgAYILDggyHrhAQQXFoKsqMECatAKRCQwgEDiaNIMGACozMEAwwuvQuKEyhmAAQgLGCDInCA4AgWUFCx5EiAAbwAUFET4DsOwAM0EFEgZWaNBggoEExUsT/3SgOrd5pwjKhwefHjzpCbMleIcAgIIBChEMfB49G7zABuoJ5AACDJw2EGkFKTDBeQwqld5q60VowGntATAhAAwsCGAEAIzW3ECp+SfQAwoU+CGCBKXX4IpGPShQhRVeGONpF1p42mgGhWiQiwKhOJCKLAYZFI8XGDABAhJ8Z6OEp+VXQXoXdEhbQeRFKZAEFBBowAKxpfZdZgJFkJ2QZPbEYwOjTZCfexQqeWED+TFAAWtTFiSBgQDkZwADEKZXGoQNMEBfmYSCtYB+EaUHZqGMclUiZA4dCmGjlFZq6aWYZqrpppx+5YBjFyAg6qijXuDYop2m6tMDT1KgIGkWkP8gKw8a1GqrrTzISoIF7ymQZQWQqipsSw0MF4F3H5DwhQYhhBDAs9BGK+20zzarwRckfGBkBAgk8OGw4HpUGQTebfCFEs5Sq+667FarxBcbGAnBAqiGa69EFVCQJAnMtuvvv+2GoAEJBmAp3b0IJ9TAAvlt0C/AEEe8rsDxRrDAtwnbu3B+U4BAg8Qgh0wtDSBMYYDFGGfcaQW8kQACBiLHLHO0GIBAMAQHq5zpgBJ8oMTHMwctNA1KfCABcTpXmgBvPKQr9NNPh8BDbyImTWYFCligAdBQd/00DRpY4JnVQS7Q88tep911zUZzSbZ5Zn8Agtp0pw1C22+DlsAEctf/7bfdH0xQdd6CkWjB3H8n7jUIYgdLuF8N2KcBzIpXDjUGGtyX8uN3LcDAFFxbLvrQUzDgNud3OaDAB06P7rrQIXygQL2ow5Xe5K/n/jTmAdbulgMTbOCB7sQ/7cEGE9Du+1kXMKBB8dA/rQEDVi5/FpysR6990LEzZ31ZD0gwBeXbly8yBlNI4Pj3XhWphPnwy6yEAdWzv1UDEHwwfPz8h+zBBxDYnP2m0p0NkK9/CIQYBpAnwAE+5QEM4EECJwgyHjBgfQ58SgUY8D4KehBiSmBAzjLYlAUc7oMoBBjjTkfCpZhwfymMIbs8YAEWtvAoELAADGXIQ2rRcFA3NEoO/3fYwyJG64dBLAoENhA6IzrxWTTYABCT+JMlHvCJWFzgFKm4EwroEItgPKIF5sTFnbwwjGh8Fg1tWEaanDGNaVxjG22SGiLCEYweUNIcZQJBxN0RjiC44B5h0gAJdPCPd1SCBBo4yJJMQIKIRCQJJsDIwhRrcBHpjONIxMbYhOpiHSLjQHzVEFKaZImRRKQGTsCHLSrGPoiiSIVA1DuBHKo0NMLTizq5I156xIRXTGUWp/AHG0CBfrlJUm8EMpwHLKAxCGDZ2ABQgQgowEoVwh90akkeBoDnAauZ0HMCWBwuOQACCvAVbKiDGeOUBIKtEyYWo8iHDghAAGswAAYNU/8B+s0GNumZjaj21BoH9DMC9plThbxDAd5MSiBFEmWPjJQk+lwoAQpAAG/ow5/v1EgkhTykPLEYAgv04Z4oZcFtFMObc24pPNKpkH0SkB/YwGc9D1hmarr1Jx4d6DQAyqUt0XkhD/VIlyCBAAlGGkYlWCAJKEVpB07AocQAaEJJWtAsYfQdHElpPTsFwE4vmYDKfDQzNbrQhRKamhvV6aMgqYAFgslUGWKAB4WwQVSjesz6FaZIEBBVksCpR64moEjRPNl6AiWBBNjnoVeaEAKsuaQlFVU/h3LrT0XiAAbEs6523cAKILHXveZzn4HxTnMSulUlyXQ23quQ5yZUy9j/6EkCUUqrUCFIW80eVSQK+AJojUjDI4ShtKVdwYIa+ZELfICuw/UgCAxwCOQi1wa1Ze5FOvvZ6HqQByeIhHWtCwZ9ancjERCud1O4wBWcYbzjVe55MyJX6K6Xf/9bhD3ha13s+rVBpsTaZELiqoosBzbgdCcA4FTVgxTSj/edIOM4wV/+rmGlLLoQeY6kPIvUyDKy1GNp7jOi7BZnqRGm4BdOQIkK83eqrvyLcSSTnAOL1ZrX/C1vkAOAB6CTArBp5jMHJE1WmbIz0PnMoY5WGQj5WJ1ijSY6RxgoIHIpp3WCAIYHAqDxpRiBGCCBGjLh4gonQY+CeU985lOcwI6G/0sX8g6WOnukDIVHoF7ijwSSxCWEIskADrBPgUhEGzoTSKsEJQ2q+jk48oxJrLEkCATgAAcLiPTL2zueH/ZbZv6yAKl/kZGbgHqBY5XnouUp0mfsQ1jphBVHYR0QdkZNJ+cgitUyRXN4DOIkgnDTAD44QBTQkD1Ma48OFhBFp8t8TF/qRdRsAgB8LoDYJYXVsLN8NW12SucF8CbaX8W2a3UNpP+8uSC1jIAbDsDuA0ghBSRoorFdFzZLLLvTaXg0YKBt2cY+1trlyWkEEiABBkQI0quBtWpSM/DRuKexqqONwAlucMMS5FCQAp5kkZZTFiYgBS5oN7tdsAUDfMG+8/+uG/rUsIl7d9oLLw0Mvy90y9GE8zRhnU5WIZPt8ih8NbzJ0Lj16VWzGYnn464aeSDkpdL4R1HX2YLIRe4DLZww5ZWjJ2ld3ukj6LuMWu7wggVFkI+HfOoij4IQNtBdrHetpLA4LtdfHvM2BoqSDobPtxQgdbSjvQwpAJ3b1ebU6s793l6fL0McAHK/+90FbjAA7gYvtLsWQryHvzfMna14CKzb8Y6v+tUpH7MF/uG9mXd54hWPEPIEG/SgVzvbSe8/CyxC7qm/N3ZHyPoXGQH2wD8A4AVPexUaYBe5P/yne28QBkQh+MB3gRG0hvLiB4AHFrhD8g//BkAznzNogD7/9Nughb5Zf1oLVAPqtz93JMR4vgqQgvjFLwchkKDtlP+fHTjNfq6zYcuKlxrPN3/itwUpwAPyNniMgwv9l3odUHesBwE/0ANoIAVnR4CwJ33UR3tfYAGg0IC5lwagpl0AAgMFMAM/YABGMIAYCHrkZ35YF2ZqcAkgmHvdJ3Z7tAA/UAA8WAAwEAM7IARb8Hot6Hf1RwJ2FGGatn41mHkn8F/MFQEz0INUKAY5YABwIH9FiHYkd4DVx1TIVgq414SZt3rzBSA6QIVqqANZwAQp4AZEuIXs5gPT9zwRFjaxQIbbd0yoNUcLYAVqGIg8aAY5QIEWKIftFgXlRwfetXLa/6eH23cCkNVIUiiIlqgDKJgCK4iI7CYF9peEkRRFocCEkJh6R7Bc52UAJmiJrAgDVBCEZRCHLdiFPPCFYFRSujCGpZh6N3heFcAErBiMPSgGVoCFcoCIdKg1wuRUerCLDQiBg0QBMSCM1FgAbBiEcCiHw1ZscHRXH/CIzsh+adBgjSQBTVCN6EiIPaAFh1iE7xZvaZR+pBiOufd/2kUe6JiP1jgDbmgEbVCEJGdytuhBNGQHukiPuQdzmFRGOqiPDumKPSAEZXCB8+cDlXZpPDRdenCQCJl7SDCJYDeNDjmSxGiMLbiN+EdB2OcJHVmDRzCCXDQB5ziSNAkDWRCEQ/+Ige+YgAmUfoPQkjVoj4MEIDRZlD3YBFfIjgQYkCf3Qfo3j0CZfNjVhzeUAMBolFiJif34j+InehDWP4xTCxwZlckHjVyEAFSAlWo5iFRAgRMpfrKXktDTga9AlmTIAhJVRhGQBWvZlydYjJsIfcPHk8Qjg41gl2S4BjAZRDLpl375gzgpi48XeZMXPcfTClCJmNt3ZoNkAI75mQWAlFiohbDnldGDbIgwlpqZfMeEgxn0ADsAmqDJhm7oBlwZe2snl38TNqywmpCoa1RUATsom7KpjhVIkX8XeISpclOwAeDom034kXOElsRZnSeYgoH5eHU4kEOzAaiQmdDJfnj/OUfSaJ3WCZkSKZns9oJfSTclNQmEEJ6QqJhzpAAzaZ7WWZJwcIxGaH+6KT8WsJHyCYlggIoxeZ/4aZ3X+IbqaYAImDbe2AkDWordN0eemaAYWgDG2Y7tpoGVGTQ+OaGleEwWmqEmiok/oIm3uZ7l1561ZwepIKKliF0LSUIO0AMmmqM++IoSSZFHCIrGlwuqKaP9B5xVOZw6mqP6yZ8HQIvcGS3Y9wlE6oxG2kIJgKRJmqM2iY2vl4x2CDDpNwtTSqVQSEJXmqVoGpqFyI4hp4gfwIj+8j+uAJ5j2oAsAJJs0RjNUSzONGAToUkX56cWoTqiVCyLkmBuQyKQdQE5/5CmaaqVKupun8gujHMKQ1qn/XenCvEk0SQRBfYQhDoiosJChvofy8ES+eE2h2IqSCMRs/QiVRoRJdIcNBUgI0ZGRVI1CCCSjpqmEIkGseigdNWBsoCp4aipeTch3nFzDuFVzbpSt8pM+TEpOYWnI3EoyzUan0Ic1aQAvjEg4AGu9ZFOEIB0uqokTwZkAtGtvuEc6UQBqJIap/MnnNFjPnInKcKrveqoMwCYZVCHNEMCG3CYxuqMyLojJNZjFbBkwSFk4NGtVoIjDXAZCyYZ0VEQ8lqvWDZRvaNllQQSs+EA5MEh7XEo3MItYRVWR0MBDJAdr7oehmZnJjtZGnUfCP8gOARhHwXhUwJSMD9iAB+yq/s6tD4IhEKgBSmQPcezCpJQsMeKpzWHAJAhaJMRUKpxUAn1VY8ibXziHY6js1Tis7D6UKnBeyXxWKq2HkVyJFySsuXhWCVCGy/bHmnLamvrTvmBsgmCVDybJ5GmIy+ir0Tbq6JJGhtgAYgQn05rsNaqJaQBZwaSHtJRU1wrJelxZZLlUNcBar02tuhmrSKRU3tmcBEiGaRBAW6bWNHhHQcHq8ORdMXRGkBGLqSRM+m0swGCJhAIuMUhuIPbq1pJGie1uIyLEM3xAPYhVAfnVTgyGkmyGm01KlVzu1x2bj8LWSZGEt6RsHSLuiabU3z/YnMPUgFJ0ro4dTIU5xzeezIQYCr2UT9aVnYbFa7ekVFIUySLIrS/O7g/2AMGUAJpwH/E24QHu7PIsTSnBnGzhFgHJSUOMFgYYjqHxULxKyD1KyrCMb8D0XEscUtg0h7kSxreYx8S4FDdUTDlO7dKYnQTABkhfDITOxtyUhCHIiIjtm037B/Yka/7O7T9agAogAUtUAMvsAJeMMB6WMBl1xpHA6v69KosC8NflRqLpBykIQE5U8PMlMMWMmI/65pgIR8RkbE/4rs9bKLqWARBMAIDMAIGQAAEMAYnAAVITMCgixJiDBFVlqfL5BAQxLdmfMbmuaU3cAVAMACIPAAm//ACcEwAQ1ACbFDHIKjELZEa75d3ABgYjCrIGfrDQZzIoMwFRNDIBFADT3AEAizJmUfJVoqlnFychVgEXMDGoAzKVyADpEwAGSACK5DKqsx10slFZ/rKoLmlLXAFS1DLyjwAKhAHuQzHRHACevXLmRdpSTTMxNyXP+wEWLDM3nwDNfDMcDwEBgBV1Dx3sZpBN5rNapnGs+zN8PzG4gzHNVACR3DOLveANUpCF8rOD3mTx5zM8AzPJiAC89zIu9zL+NxprdlG/ezP1ViS3DzQFD0AQVAFB43QRIAE07zQ/EWibdSYEB2MZtCWskzLFT3QOIDLGd3IXXAC5uzR4yWUZf9knyMtiLQZ0Cm9083c0qTMASWwBjI9XmCwmCRUnjc9jMU40Tvd1DfAAT5NymQgAizgyzI9jtOZljdd0j1wA+/c1GAtz1GN0FWwAh091PfEyjcknBCd0ygg0GAN1kvwBGP9zDJwAm+A1ihllkEEm+ws0UEQ14KNyFjAyHWdy3FQAmCg1wq5Rw/dw1zt1Yc82IO90of9zDUgAgE81CA9RyL9u24N15Q92E4wBJf9zBlQxEfs0WDwdVy0l78L2KM924hcBFB92s8sx3S80Fi9R9S5r664A5JN28RtABmA2+L8yJGMz8E8R1bpqFrZAm9N3NQNBCWA3PNsyqhMzfo8lI//baJWaABOENjUXd6LjN3znNBW7bTd97Ek9NkYGtzDXd70jQNjgN4HHc1nPcAFylwQEMizyY/SbQL0XeCIjAJdgN8HTc4xPcAscMlJ1JDmGd4qsMYGfuEqcNsKLs71fM9IzNdchI/EKd84MNkXfuEGQAYbftDqTby9yFzm+JnRjQIEfuI27sYrntEZsNH7XadrYKDRCOAOSeEWbuNGft45ntEv3eB1igR5uUe/qJaQeQMlbuRWjsiinOQtDdRCjamNnYqr6JAoOuBXXuYDcMta3tJTXdV1StPaVYn6iJQ9UOEobeZWnuFp3tIZUNY9PqArAOEMCYjVOOVVbud2PsR5/+7Td53XMvqAnMdFaBiMKArENW7ohi7WiZ7Rib3YInpm7k1FcB6Icq7GdW7pZl7QmR7Vmb3Zfg7obSThPTjlhmzqtG7RGJ3qPp3aRiyfMGe2jVSC+5iCn1zrtW7ZuB7Vuh2eYEC6vRcBORDLRU7std7Txx7Vyg2dTv59RYICJi7txA7O1T7W2r3e9MiH3wcg5O3t0o7p4a7nvEzuzniK3ycQEFAE6i7tJkDX7V7X+k2WmzfvkFbp927phb3vh83gUbnsAC8QE4ACA0/rxm7w4m7PLTlVd6xdh9LtD1/mpS3xh93i9HhmYKxdEuDwG2/ntu3xH8/j9Oh+C88ZBqDxJ/9v4+yu8lG95M4o8i8/ECU/81e+BNdt85fN5bvo8jsPUTHv80du2EJ/2GsO76mn80d/JSav9Bdu301/2ntu1mRo9FM/HUlv9QaO4FmP24teg1L/9QAgAU4g9gaO52V/2pvegB3g9WrfTwLv9rRt3HGP26sO9Z227CP/fQpg73pP3EBQ830/1rq+2qnnBZKo9gWRU1xw+LSN5IuP28meevn26fNOAS1Q6pYP1lme+ch97Yd3TL7+9YFS9aMf12hu+sg97u1n1F+P968v2HAv+7gN8stWXoO/8wpwA6Kf+wPdAirO+9jd752GXRf/9Z11Bca/0ziu/OiN8GUmX5K/EEX/kvfTv8yobv3o3eEuVl5Uuf2sQfzfP9AXLf747fvXlb3oz2UM0Pbr780R7/7IveMcDRACBA4U2AHJBAAJFS5k2NDhQ4gRJU6kWNHiRYwZNW7kaLGCgSADRI4kWdLkSZQpVa5UqSIOAZgxZc6kWdPmTZw5ddbsciIJwYFHGADqWNToUaRJlS5lSpFCiyUspU6lWrXkjRo7tW7l2jUnhxJrgCYxUKnpWbRp1a5lK3FCkRFW5c6la8DrXbx5cZIRwaKDQBsnbLUlXNjwYcQOHTBwQtfxY5UmnuilXBlvhiorbHRYQYpWYtChRY/mmMAADsipVQd5Ydn1650yTrAYStr2/23cty+AVN2bLg4ZsIUPn0nEAKbcyZUvZwsBqm/oVJ0MIV4d9hADC5hv59696IQWQKKPV1mEg3X0lGsYgODd/Xv4Dxu8jUvePkm76fV7rVEiQnwAA3RvMbjuu2+JyfZTcKcMnpigAQEjlDC5BxgowkD7sGhtQQ5tykCEBycUcUTRKkQBw/FwGKNDFmX6kIEHSJRxxsJMRBE6FLposcUXY6TxRyDPsvFG1VQ4b0cOewxySSaRMrE+Ih0zIAMkF1SySSyzzKjCAqOcC4gSqlTwSi3LNDMiLqH0kioTNhQTPTLPlHPOhB6QoIio1qQKByLeRK+/CRygc1A653tOT6muCP/OT+LACpFQSM9s4BHeEF3JSEaHwy4CCCP11Mw9DLjCUpVaICNT2MYwgIJPWzVzAQNUUJNUkUbID9XKMnghO1c/deACBBboFK0HFNBOogUU8HGhCDhVKAEfG0hg2mkhpEABQRXCY44WTKCVpDZxrayGJ2Ds1VNYDVBXAbUcQCABABAwAF6H5KVXIXvrlJddAExTV114G5CAX4Ua0OS0b0Xiogpx9erCAAWGPXdQBwxgAN4HEACggWshiNHdCq7VeGMIFEDg3Y0RUCCCCvpFoIKSW3Y3AQcUYE+7axXwON55F2qAgfYSshnihKRNIN1sYb1XoTpiFY9W4Bq+CzMDRp7/GNLdWF1oAgYQ4NoBfxVggNcJVoWgagC49tqAjC0eGuyq7TRgAlYlQIACBiTgeemPljaN4ITODjqhVR3atgUsaHVJ6q7AuvhqT+W1GoAHCv/oAtM0/uhd9vqNG2IEzj65ZwrmzXzvhBK4dmzU8TWAob8XqtiAbIUG3OdADHBi1iixYlyrDFR1FvJIYSUYbo0zP115tJk3+eQE8rX39Hw/Yrns1hOSF3aiFRKcIQVuZ8gRBhBH9NbfceKg3AuIb1UC0CNgN+8EImB7+aobMEAC1dFmgIEFJOACC5Ce6dAmuehVrQLwyx4AYLWsB+xmAgmAkL9qlxCgSaQBuVPB04hk/wIRpA8nGTAOttzXKgfYb3/te0DZJKAd/GlsAWOzmcYeoEIJVKCA00KbA+DHKRcyMF8KqZjVhgYwANhMa8/i1UQSAT8c8M4+rBGhTbpQAga07IRbRNa07KdFtUCAARekiAL0VhFG1KEFNwgJiqJWRZlwQASrkhgX7ciQs+1vcmn52aMocralUcQBpoiVtww0HTjChAxVgNiy7vhIM+EhD4W8j3ngSML9gRGSmzSTISaJAkNGB32My4AMsHgsTqbyTI4QBCV9g6D0kYEIWERAHVV5yyx5MlZtTI2GGFcD49jNlrgkJpYSQakbRBEyb8TVEHb1wmJGc06K2EMLDICCxP/RxQk6yhQZxlACA0QgkNIkp5YYMYpJ3uAKeaoKpt6UgSHM0W5kLGc9y6SIOszBAOpkJ0umVCV4MpI9mrRnQeWkij3oU53ZTAmYdlSDLuwqnMIyaEUhhYc6tFJ3XOjnSMK1IDIMgQhPsBgEKjBMi6ZUTg5YwC302QIV4MAE9VGRfjjQhSqQFHSOVGlPPcVSCJRtnypQQRU4QKXXcGAIMsipuiQQAZT5VKqQE2DJ/mUAEbygCjKQQRc48FWwhhWsS5UBEV4g0XVBlWZTZesdE6BDBMhPbFelK13D97wAorSte+VrX/36V4s8gFrT4ulaarZEaWULbIPdWLMA+9j3HHH/XYYRW6fqhzaeXbVOmIVsZ5cjWMFBK3oPCKADSqYACkCIgAlZbfQq0KwGqOxYyVoZQU2Dyn+NbLGlOyMAxKhXzwY3NJLTnsWqlgCTfc9mQnudvBhQtueOTVARoAAC4HfB0jGEuAuBHypNQ1Dhhne4mJUXGBdgVXYtN4nN7RnR8uUuM/ZMIeHTLmcduD+G2Fe8+0XMdodYOgrETr3LzZd757WYCZxXvrar7+S6m9898lfCbfGvfG1WAeMBwH7UZV2B2TW9cCJ3wb5lwEISENri9nazqJxwi9dSYXpVCGJEk1sEsOdh1J3tuSNWmkLourGxEVRe9HRxkWUkAYRc5GeDUzNyk2VkGiZrkGvAdXKVrXxlLGdZy1vmcpe9/GUwh1nMYyZzmc18ZjSnWc1rZnOb3fxmOMdZznOmc53tfGc851nPe+Zzn/38Z0AHWtCDJnShGxIQADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     The numbers in parentheses associated with the pie graph represent the percent of patients with each cause.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18206=[""].join("\n");
var outline_f17_49_18206=null;
var title_f17_49_18207="Diagnosis in adult heart transplants";
var content_f17_49_18207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Diagnosis in adult heart transplants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 504px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    1/2005 to 6/2010.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Stehlik J, Edwards LB, Kucheryavaya MS, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report&mdash;2011. J Heart Lung Transplant 2011; 30:1078. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_49_18207=[""].join("\n");
var outline_f17_49_18207=null;
